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 Prostate cancer is the most commonly diagnosed cancer in American men and accounts 
for approximately 11% of cancer-related deaths.  Although promising treatment strategies have 
been developed and are currently being tested in clinical trials, standard practices in the 
treatment of prostate cancer remain inadequate.   This is due in large part to the heterogeneous 
and multifocal nature of prostate tumors which severely complicates efforts to stratify patients 
and to identify therapeutic targets to effectively treat prostate cancer.  A better understanding of 
the molecular mechanisms that drive prostate cancer initiation and progression to advanced 
stages is needed in order to design effective diagnostic and treatment strategies.   
The transmembrane protein with EGF-like and two follistatin domains 2 (TMEFF2) is 
selectively expressed in the adult brain and the prostate and is overexpressed in prostate cancer, 
  
suggesting a potential role in the establishment and/or progression of the disease.  Previous 
reports on TMEFF2 function have revealed a complex biology with seemingly diverse cellular 
effects, and its role in prostate cancer has remained unclear.  The studies presented here examine 
the biological function of TMEFF2 in prostate cancer in order to evaluate its potential as a 
molecular target for prostate cancer or as a diagnostic/prognostic biomarker.  Data obtained 
using prostate cancer cell lines pointed to a role for TMEFF2 as a tumor suppressor as its 
overexpression resulted in a potent inhibition of anchorage-independent growth, reduced 
proliferation rates, the promotion of apoptosis, and a decrease in invasion.  The tumor suppressor 
function of TMEFF2 was further demonstrated through the inhibition of subcutaneous tumor 
development in a TRAMP-C2 allograft model.   
Evidence that TMEFF2 expression can be upregulated by androgen stimulation in a post-
transcriptional fashion suggests a potential mechanism by which its expression can be modulated 
in prostate cancer.  We therefore investigated the post-transcriptional regulatory pathway 
controlling the expression of TMEFF2 in prostate cancer cells and its connection with androgen 
signaling.  The presence of conserved upstream open reading frames (uORFs) in the 5’ leader 
region of its mRNA transcript prompted us to investigate the possibility that androgen signaling 
stimulates TMEFF2 translation through these regulatory sequences.  Our results show that 
TMEFF2 translation is inhibited by its uORFs under normal conditions; however, the uORFs 
mediate a translational increase in TMEFF2 expression in response to androgen stimulation 
through the phosphorylation of the initiation factor eIF2α. This effect is dependent on a 
functional androgen receptor (AR).  During the course of prostate tumorigenesis, the selective 
translational increase in uORF-containing transcripts by androgen signaling may represent a 
mechanism by which certain transcripts are selectively regulated to influence tumor progression.   
  
As a tool to study role of TMEFF2 in prostate tumorigenesis in vivo and to evaluate its 
potential as a biomarker, we generated and initiated the characterization of a novel transgenic 
mouse model with TMEFF2 expression exclusively in the prostate epithelium.  Ultimately this 
model will be used to study the function of TMEFF2 in the development/function of the prostate 
gland and in prostate cancer. 
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                     CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
The hallmarks of cancer 
 Tumorigenesis is a multistep process driven by a succession of genomic alterations that 
confer a phenotype of uncontrolled growth and survival.  The specific genetic or epigenetic 
alterations that drive tumor initiation and progression can vary greatly in distinct forms of 
cancer.  However, a common set of phenotypic traits or “hallmarks” have been identified which 
are common to most cancer cells and that are critical for malignant progression.  These traits 
include increased proliferation and invasion capabilities, resistance to cell death, evasion of 
growth suppressing signals, angiogenesis, and replicative immortality (Fig. 1)(44).  Each of these 
traits plays a distinct role in the disease process; however, they are often controlled by 
overlapping signaling pathways and multiple traits can cooperate to promote tumor progression.   
The acquisition of the hallmarks of cancer during tumor progression is driven by certain 
characteristics of both the cancer cells themselves and of the cells that make up the tumor 
microenvironment.  Genomic instability is one of the drivers of almost all cancer cells (60) and 
serves a critical role in tumor progression by promoting the selection of traits that provide the 
cancer a growth or survival advantage.  The onset of genomic instability in cancer cells can 
occur through a variety of mechanisms that are often dependent on the type of cancer (60) and 
generally involves the loss of function of DNA repair or checkpoint genes (e.g. p53).  
Additionally, inflammatory cells in the tumor microenvironment accelerate the accumulation of 
genetic aberrations though the release of reactive oxygen species.   In solid tumors, many cell 
types that make up the tumor microenvironment, including inflammatory cells and other stromal 
cells, are capable of directly encouraging certain hallmark traits of cancer cells by supplying
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growth/survival factors and extracellular matrix-modifying enzymes (44).  A complex interaction 
or “crosstalk” between the stromal compartment and cancer cells has been demonstrated to play 
a pivotal role in the establishment or progression of many types of cancer, including breast, 
prostate, pancreatic, and lung cancers (20, 29, 98).   
Stromal-epithelial crosstalk also plays an important role in organ/tissue development, 
regulating processes like differentiation, proliferation, survival, and branching of the epithelium.  
However, it is now evident that many of the molecular pathways involved in the stromal-
epithelial crosstalk during development are critical drivers of tumorigenesis.  For instance, the 
stromal secretion of matrix-degrading enzymes (e.g. MMP-9) that mediate branching 
morphogenesis during development serves a crucial role in the invasion of cancer cells into the 
stromal compartment (94).  Additionally, two stromal-derived signaling molecules with 
established roles in prostatic development, Notch1 and Shh (sonic hedgehog) are now implicated 
in prostate cancer metastasis (7, 69).  In fact, the re-activation of early vertebrate developmental 
pathways including Notch, Shh, BMP, and Wnt, is a common observation in the progression of 
most cancers (7).  The activation of these pathways has been demonstrated to drive a variety of 
hallmark tumorigenic traits, and the mechanisms by which these developmental pathways 
instigate tumor progression largely depend on the type of cancer.   
The identification of these hallmark traits of cancer cells and the features that promote 
them has provided an avenue to therapeutically target the specific pathways that drive tumor 
growth and survival.  Several drugs have been developed that target one or more of these 
tumorigenic traits and have shown efficacy in clinical trials.  However, as previously mentioned, 
these traits are often regulated by multiple signaling pathways which are capable of 
compensating for one another in the event that one is targeted therapeutically.  Additionally, 
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tumor cells rarely depend on just one of these hallmark capabilities, and highly advanced cancers 
often display several if not all of these hallmarks.  Inhibiting specific tumorigenic traits has 
therefore proven to be a promising but complex strategy to treat cancer and requires further work 
in identifying biomarkers and the molecular pathways that drive the tumorigenic phenotype. 
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Figure 1.  The hallmark traits of cancer cells.  (Adapted from Hanahan and Weinberg, 2011 
(44)) 
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Prostate cancer background and pathology 
 Prostate cancer is the second most deadly cancer for men in the United States with 
approximately 30,000 deaths attributable to the disease every year (1).  If detected early and 
confined to the prostate capsule, these cancers can be effectively treated by radical prostatectomy 
and radiation therapy.  Although this treatment has a high success rate, patients with advanced 
prostate cancer do not have a treatment strategy that will improve their long-term survival.  The 
current gold standard for treating advanced prostate cancer is androgen withdrawal, which entails 
surgical or chemical castration and the administration of androgen antagonists.  Androgen 
withdrawal is effective in causing the cancer to regress; however, it inevitably returns with an 
aggressive phenotype that is characterized by deregulated androgen signaling (Castration-
resistant prostate cancer, CRPC), and for which there is no cure (73, 92).  It is therefore 
imperative to gain a better understanding of the mechanisms that lead to the establishment and 
progression of this disease in order to design effective treatments and identify novel biomarkers 
for its diagnosis and prognosis. 
 An insufficient understanding of the molecular pathways driving prostate tumorigenesis 
has hindered the molecular targeting and personalized therapies which have gained traction in 
many other cancers.  This shortage of information on the molecular basis of prostate cancer 
initiation is likely due several reasons.  First, the heterogeneous and multifocal nature of prostate 
cancer makes it difficult to obtain homogeneous samples for analysis, and to tease out the 
pathways that are critical for its survival.  Additionally, most clinical samples are derived from 
highly advanced cancers that are characterized by a plethora of mutations and other genomic 
alterations, making it difficult to determine the genetic cause of progression to each stage.  
Furthermore, understanding the disease process is further complicated by the transition from 
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androgen-dependent to castration-resistant prostate cancer that occurs during disease 
progression, which is accompanied by or driven by alterations in several molecular pathways that 
allow for androgen-independent growth and survival. 
 Few “signature” genes have been implicated as hereditary factors involved in the 
pathogenesis of prostate cancer.  The vast majority of prostate cancer cases are sporadic and do 
not involve hereditary factors (57).  However, a few gene alterations have been identified in 
families with hereditary prostate cancer that are believed to drive disease initiation and/or 
progression (reviewed in (57)).  For instance, Ewing et al. recently identified a mutation in 
HoxB13, a member of a key pathway in prostatic development that is associated with a 
significantly increased risk of hereditary prostate cancer and early disease onset (31).  
Overexpression of HoxB13 has been observed in CRPC was shown to provide a growth 
advantage to prostate cancer cells in the presence of low androgen levels (54).   
  Genetic and epigenetic studies have identified numerous sporadic chromosomal 
aberrations that are frequently detected in prostate cancer specimens and are associated with 
certain stages of progression.   Although the specific roles of many of the altered genes in driving 
the disease are not fully understood, in vitro functional studies and  transgenic mouse models 
have demonstrated that modulations in their expression can be driving forces of prostate 
tumorigenesis rather than secondary effects of tumor progression.  The proceeding sections will 
briefly review the stages of prostate tumorigenesis and reference some of the most common 
genetic/chromosomal alterations that have been associated with certain stages of progression. 
The human prostate is divided into the peripheral, central, and transition zones.  The 
majority of prostate tumors develop in the peripheral and central zones in small glandular acini 
which empty secretions into the urethra. Each acini is comprised of secretory luminal cells 
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which, in healthy prostate tissue, are surrounded by a thin layer of basal and neuroendocrine cells 
(Figure 2; normal epithelium).  The tissue surrounding the acini is a fibromuscular stroma that 
plays a critical role in prostate development, epithelial cell differentiation, and in prostate 
tumorigenesis (20).  Prostate cancer first appears in the epithelium of the prostate as a 
hyperplastic lesion of cells, a state known as prostatic intraepithelial neoplasia (PIN).  These 
lesions are a result of unchecked proliferation and/or a reduction in rates of apoptosis in a subset 
of the epithelial cells that line the glandular lumina; however, at this stage the cells are confined 
by the basal cell layer and the lesion does not extend into the stroma.  The loss of chromosome 
region 8p12-21 is associated with this early stage of cancer and several studies point to a role for 
the NKX3.1 homeobox tumor suppressor gene, located in this region, as a cause for driving PIN 
formation (11, 12).  Transgenic mouse models that target NKX3.1 for inactivation display PIN 
formation that resembles human PIN features, however it is not enough to lead to invasive cancer 
(11).  In addition to NKX3.1, the MYC oncogene is frequently upregulated in both PIN and 
prostate cancer tissue and has been suggested to play a role in the initiation of PIN (42).  The 
chromosomal region which contains the MYC gene, 8q24, is amplified in several cancer types 
including prostate cancer (51, 56), and its oncogenic function is well established in vitro and in 
vivo.  In support of its role in prostate cancer development, Myc overexpression in a transgenic 
mouse model leads to the development of PIN and adeno-carcinoma (28, 50).   
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Figure 2:  General stages of prostate cancer progression.  Progression through each stage is 
associated with gene alterations (chromosomal aberrations, mutations, epigenetic modifications) 
that result in the loss of tumor suppressor genes or the activation of oncogenes.  The deregulated 
genes/pathways have been associated with certain stages of disease progression based on 
expression profiling studies from prostate cancer specimens derived from different stages of 
progression.   
 
*This figure was originally published in Genes & Development. Shen, M. and C Abate-Shen. 
Molecular genetics of prostate cancer: new prospects for old challenges. Genes & Dev. 2010; 
24:1967-2000. © Cold Spring Harbor Laboratory Press (90) 
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Following the establishment of PIN lesions, further genetic aberrations lead to disease 
progression to prostate adeno-carcinoma, when neoplastic cells begin to obstruct the glandular 
lumina and invade the stromal compartment.  These cells are no longer constrained by the 
basement membrane which in early stages of tumorigenesis acts as a mechanical barrier to 
prevent malignant cells from invading surrounding tissue.   Cases of prostate adeno-carcinoma 
are described as latent if there are no symptoms for the patient or evidence of spreading to other 
tissues; and in many cases these will remain latent.  However, they can also progress to clinical 
adeno-carcinoma as cells invade the tissue surrounding the prostate such as the seminal vesicles 
and/or bladder, often coinciding with the onset of symptoms.  Some genetic aberrations have 
been identified in a large fraction of postate adeno-carcinoma specimens that are believed to be 
involved in the progression of the disease after the initiation of PIN.  For example, region 10q-
23.1 is frequently lost during prostate cancer progression at some point after cancer initiation, 
and this genetic alteration is rarely found in PIN lesions (88).  This locus harbors the phosphatase 
and tensin homologue (PTEN) tumor suppressor.  PTEN dephosphorylates and inactivates 
phosphatidylinositol (3,4,5) triphosphate (PIP-3) and reduces signaling through AKT/PKB, a 
pathway that strongly promotes cellular growth, metabolism, proliferation, and survival (15).  
Decreased PTEN expression or function is frequently observed in prostate cancer and several 
other cancers including glioblastoma, breast, and endometrial cancers (86).  Its tumor suppressor 
function in prostate cancer has been demonstrated in a PTEN homozygous null mouse model 
which targeted both alleles of the gene for inactivation exclusively in the prostate.  These mice 
develop prostate tumors which rapidly progress through the entire continuum of carcinogenesis, 
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from low grade PIN to metastasis (105).  Another common chromosomal aberration that has 
been implicated in driving progression past PIN is the TMPRSS2-ERG gene fusion.  This fusion 
results in the androgen-regulated activation of ERG, a member of the ETS transcription factor 
family. The functional consequences of ERG activation are not fully understood, however it is 
believed to inhibit epithelial cell differentiation programs and cooperate with other oncogenic 
events to promote disease progression after the initiation step (90).  
The invasion of prostate cancer cells into tissues surrounding the prostate puts the cells 
into a position to metastasize and colonize distant sites.  If cancer cells are able to detach from 
the original tumor and enter blood and lymph vessels, they may colonize distant site(s) and form 
metastatic foci, representing the terminal stage of cancer progression. In human prostate cancer 
the primary site of metastasis is the bone, but it can also spread to the lung and lymph nodes.  
The progression of localized prostate cancer to metastasis is a multi-step process that requires 
dramatic changes in the phenotype of the cancer cells, as well as the cross-talk between the cells 
and the surrounding environment, to be able to survive and colonize foreign tissue.  The 
activation of oncogenes that drive a metastatic phenotype and/or the loss of tumor suppressor 
genes that protect against metastasis provide the cells the ability to spread to other tissues and 
survive to form secondary tumors.  Although an abundance of genes have been described as 
having roles in the process of metastasis, some of the most common gene alterations detected in 
metastatic prostate cancer that are thought to play a causative role in late-stage progression are 
mentioned below.   Late-stage prostate cancers commonly show the loss of a region of 
chromosome 13q, which contains the Retinoblastoma (RB) tumor suppressor gene (61).  The 
protein encoded by this gene is well known to have a negative influence on tumorigenesis by 
antagonizing transcription factors of the E2F family, and its loss leads to increased expression of 
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cell cycle genes and increased AR activity (89).  Additionally, mutations in the tumor suppressor 
p53 and allelic loss at the p53 locus, 17p, have been detected primarily in late stage prostate 
cancers, although the frequency of these aberrations has varied greatly in the literature (18, 88).   
The p53 tumor suppressor function has been implicated in the progression to CRPC and 
metastasis (76); and although its effects are pleiotropic, it primarily antagonizes cell proliferation 
and survival in tumor cells (40).  In support of a role for Rb and p53 loss of function in prostate 
cancer, a conditional Rb and p53 compound knockout mouse model displays invasive and 
metastatic carcinoma at a rapid pace, indicating that the loss of both genes may have a 
synergistic effect that leads to a highly malignant phenotype in some cases (110).  The lysine 
methyltransferase EZH2 gene may also have a role in late-stage disease progression as it is 
overexpressed in a significant fraction of castration-resistant, metastatic prostate cancers but not 
in early-stage tumors (87, 102).  Furthermore, gene silencing is a common feature of advance 
prostate cancer, and EZH2 has been proposed to be involved in this process.  In vivo studies 
support a role for EZH2 in promoting metastasis (97), however its mechanism of action as an 
oncogene has remained unknown for many years.  Recently, Min et al demonstrated that EZH2 
epigenetically silences key metastasis suppressor genes, leading to simultaneous Ras and NF-κB 
activation and metastasis (70).  These genes are strong candidates that may have an influential 
role in driving prostate cancer progression to later stages, and targeting their 
expression/activation may significantly impair the metastatic progression of prostate cancer. 
  Altogether, these observations support a need for multiple “hits” or gene alterations 
(mutations, deletions, epigenetic modifications) to drive prostate cancer progression.  The 
aforementioned genetic aberrations are associated with certain stages of the disease based 
primarily on cytogenetic or mutational analyses of prostate cancer specimens and on functional 
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studies of the affected genes in prostate tumorigenesis.  However, these genes represent only a 
small fraction of the genes that are altered in prostate cancer and that have been implicated in 
driving the disease process.  Newly identified genes with potential roles in prostate cancer are 
continuing to emerge, along with novel pathways that deregulate the expression of those genes 
through a variety of mechanisms.   
 
The role of androgens and the AR in prostate cancer establishment and progression 
Although deciphering the molecular pathways that drive prostate carcinogenesis has 
proven to be complicated, it is indisputably clear that androgens and the androgen AR play a 
major role in nearly all aspects of prostate biology, from prostate development to the 
establishment and progression of prostate cancer.  Androgens and the AR have been primary 
targets for the treatment of prostate cancer since the 1940’s, and although the strategies to target 
androgen signaling have changed, it remains a major focus of prostate cancer research and 
treatment strategies.   
The primary androgen, testosterone, is synthesized almost exclusively in the testes, 
although a small amount can be produced in the adrenal glands.  Once testosterone enters the 
cells of the prostate it can be converted to dihydrotestosterone (DHT), a more potent form of the 
androgen.  The biological effects of androgens on prostate tissue are principally mediated though 
the AR, a member of the nuclear receptor transcription factor family that is activated upon 
androgen binding.  Basal levels of testosterone and DHT are required for cell growth and 
survival in normal prostate tissue.  AR signaling in both the stromal and epithelial compartments 
promotes its proliferative homeostasis, epithelial cell differentiation, and secretory and metabolic 
processes (8).  The influence of androgens on these cellular processes is principally mediated 
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through AR transcriptional activation of androgen-regulated target genes, and its actions can be 
heavily influenced by a number or coregulators as well as crosstalk with other pathways that can 
modulate its activity (83).  
In addition to its classical role as a transcriptional activator, new roles are surfacing for 
androgens and the AR that are independent of its transcriptional effects or “non-genomic”.  Non-
genomic androgen signaling can influence a wide variety of cellular processes, mostly mediated 
through rapid changes in [Ca
2+
] levels or second messenger signaling through several pathways 
including MAPK, PKA, and PKC (33).  The effects of this type of androgen signaling are 
relatively rapid and can be dependent on or independent of the AR.  The physiological effects of 
non-genomic androgen actions are currently not well understood and it is not known if they are 
linked with AR transcriptional effects or if they function independently.   
The influence of the AR in prostate cancer is critical as prostate cancer cells are 
dependent on androgen signaling to grow and survive.  Therefore, blocking androgen action is 
currently the gold standard treatment for tumors that cannot be effectively removed by 
prostatectomy and radiation.  Androgen Deprivation Therapy (ADT) is defined by a combination 
of approaches to eliminate the actions of androgens and the AR, usually through castration and 
the administration of AR antagonists.  Through ADT, androgen regulated genes are suppressed 
from the molecular network of prostate cancer cells, leading to massive apoptosis and prostate 
cancer regression.  However, despite continued attempts to block it, AR signaling returns along 
with the cancer in an aggressive and lethal form of CRPC.  Several mechanisms have been 
proposed to account for the return of AR signaling, including AR gene amplification, increased 
AR ligand sensitivity, ligand-independent AR activation, and increased androgen synthesis (Fig. 
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3).  Studies in castration-resistant mouse models have demonstrated that these cancers remain 
dependent on AR signaling throughout prostate tumorigenesis (8).  
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Figure 3.  Role of androgen signaling in prostate cancer.  (A) Androgens and the AR are 
critical for the function and homeostasis of the prostate gland.  (B) Removal of androgens from 
androgen-dependent prostate cancers triggers massive apoptosis and disease regression.  (C-F) 
Mechanisms proposed to contribute to the development of castration-resistant prostate cancer 
include (C) amplification of the AR gene, (D) AR mutations that increase its activity, (E) 
activation of oncogenic pathways that lead to the induction of androgen-regulated gene 
expression, and (F) increased androgen synthesis.  
 
*This figure was originally published in Genes & Development. Shen, M. and C Abate-Shen. 
Molecular genetics of prostate cancer: new prospects for old challenges. Genes & Dev. 2010; 
24:1967-2000. © Cold Spring Harbor Laboratory Press (90) 
 
16 
 
 
 
The role that AR signaling plays in promoting the establishment and/or progression of 
prostate cancer has been extensively studied; however, the expansive influence of the AR on a 
wide variety of cellular processes makes it difficult to tease out its specific roles in driving the 
disease process.  As mentioned, AR signaling activity is critical for the growth and survival of 
prostate cancer cells and has therefore conventionally been ascribed a tumorigenic role in the 
disease.  The identification of an abundance of androgen-regulated genes that promote 
proliferation and survival support its pro-tumorigenic role, including cyclin-dependent kinases 
(CDK’s), anti-apoptotic genes, and genes involved in epithelial cell differentiation and secretory 
function (8, 68).   However, this conventional concept of the AR as tumorigenic was challenged 
recently by the discovery that AR signaling can suppress prostate epithelial cell growth and 
induce differentiation (78, 107).  It has been demonstrated that the AR acquires oncogenic traits 
in advanced prostate cancer cells that promote the survival and growth of the cancer cells (101).  
These results made clear that the role of the AR is complex and much remains unknown 
regarding its function in prostate cancer. Through both the classical transcriptional network 
activated by the AR and through rapid, post-transcriptional or “non-genomic” effects, androgen 
signaling capabilities are vast and new roles for the AR continue to emerge.   
 
The TMEFF2 gene and its potential role in prostate carcinogenesis 
TMEFF2 is an evolutionarily conserved, type I transmembrane protein expressed 
exclusively in the adult brain and prostate tissue under normal conditions, and is frequently 
upregulated in prostate cancer specimens relative to benign tissue (39, 99). It has been proposed 
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that TMEFF2 may play an influential part in the establishment and/or progression of prostate 
cancer; however the role of TMEFF2 in the disease process has remained unclear. 
TMEFF2 is a member of the relatively new TMEFF (transmembrane protein with EGF-
like and two follistatin domains) protein family.  TMEFF2 and the only other member of the 
TMEFF family, TMEFF1, contain similar structural features and may therefore serve similar 
biological functions.  Both TMEFF proteins contain an EGF-like domain similar to those 
previously described in the EGF-like protein family (100).  Another common feature of these 
proteins is the presence of two follistatin modules toward their N-termini.  Follistatin domains in 
generally are known to bind and generally antagonize members of the TGF-β family such as 
activin and inhibin (106).  Additionally, the C-terminal domains of these proteins contain a 
putative G-protein-activating motif, suggesting a potential role in second messenger signaling.  
The extracellular portion of the TMEFF2 protein can be cleaved by the metalloproteinases 
ADAM 10/17, releasing from the membrane a soluble form of the protein that contains the EGF-
like domain and two follistatin modules (5)(Fig. 4). Due to the high degree of sequence 
similarity between the TMEFF proteins, it is likely that TMEFF1 can also be cleaved to release 
an ectodomain; however its cleavage has not been confirmed experimentally. These structural 
features reflect the potential of these the TMEFF proteins to influence a variety of cellular 
process, conceivably acting as a membrane-bound receptor, co-receptor, or a ligand precursor.   
Investigations into the biological function of TMEFF1 have been limited; however, 
insights into its function and mechanim(s) of action may provide clues into the role of TMEFF2 
in prostate tumorigenesis.  The brain appears to be the primary site of function for TMEFF1 as it 
is predominantly expressed in the brain and to a lesser extent in the heart, placenta, and skeletal 
muscle (36).   A role for TMEFF1 in cancer was proposed when it was shown to be 
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downregulated in 96% of 54 brain tumor samples relative to normal brain tissue (36).   
Furthermore, overexpressing TMEFF1 in the glioblastoma cell line U118 had a growth 
inhibitory effect on the cells (36), consistent with a role as a tumor suppressor.  TMEFF1 
expression has also been detected in early mouse embryos and it may play a role in vertebrate 
development (26).  Supporting this possibility, studies in Xenopus embryos demonstrated that 
TMEFF1 is able to block nodal signaling, and that this inhibition required both the follistatins 
motifs or the EGF-like domain (13).  Nodal has a crucial role in embryonic development, but like 
many developmental pathways, has also been shown to be re-activated in cancer and to promote 
prostate cancer cell growth (58).  Modulating TGF-β/nodal action may therefore represent a 
mechanism by which TMEFF1 functions as a tumor suppressor.     
Previous studies into the function of TMEFF2 in tumorigenesis have demonstrated a 
complex biology for the protein and its role in prostate cancer has remained unclear.  Functional 
studies to date from our lab and others are suggestive of a potential dual role in tumorigenesis.  
Overexpression of full-length TMEFF2 inhibited cell growth and proliferation in PC3 and 
DU145 prostate cancer cells (35), and inhibited colon cancer cell growth and survival (27). 
Additionally, Lin et al. recently reported that TMEFF2 can bind to Platelet Derived Growth 
Factor (PDGF) and inhibit PDGF-stimulated fibroblast proliferation (66).  Its ability to modulate 
PDGF signaling could be an important clue to the function of TMEFF2 in prostate cancer as 
aberrant PDGF signaling has been associated with prostate tumorigenesis (55), stimulating cell 
growth and promoting metastasis through the activation of the AKT/PKB pathway (24).  
Contrary to results with the full-length protein, overexpression of the TMEFF2 ectodomain has 
been shown to promote growth in HEK293T cells through ERK activation (5) as well as survival 
effects in some neurons (47).  The pro-tumorigenic effects of the ectodomain region are 
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consistent with the observation that its overexpression in MKN28 gastric cancer cells stimulated 
ErbB4 phosphorylation, a member of the EGF receptor protein family (99).  These results 
indicate that TMEFF2 is capable exerting opposing functions in cancer, both tumor suppressive 
and oncogenic, and its role in tumorigenesis may therefore be dependent on the tissue type, stage 
of the disease, or other environmental factors that can augment its function. 
Like TMEFF1, TMEFF2 may play a role in development as its expression has been 
detected in the middle to late stages of embryogenesis (99).  However, the functional role of 
TMEFF2 in development is currently not known.  The presence of the follistatin domains 
presents the possibility that TMEFF2 may modulate the TGF-β/nodal signaling pathway during 
development as was demonstrated for TMEFF1; however, no studies have confirmed this 
function for TMEFF2.  In light of the re-activation of developmental signaling pathways in the 
progression of prostate tumorigenesis (7, 15, 82), deciphering its role in development may 
provide important insights into its function in prostate cancer.  
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Figure 4:  Structural domains of the TMEFF2 protein. SP=signal peptide, FS=follistatin, 
EGF=epidermal growth factor-like domain, TM=transmembrane region.     represents the 
putative metalloproteinase cleavage site, which releases the TMEFF2 ectodomain.  A potential G 
protein-activating motif is located near its C-terminus facing the cytoplasm.   (Adapted from 
Horie et al., 2000 (47)) 
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As previously mentioned, TMEFF2 is frequently overexpressed in prostate cancer tissue 
relative to benign prostate tissue.  However, the mechanism(s) that lead to the upregulation of 
TMEFF2 in prostate cancer are not well understood.  Although multiple studies have 
demonstrated that TMEFF2 is transcriptionally regulated by androgens (35, 71), the addition of 
testosterone to an androgen-deprived prostate cancer xenograft model stimulated a post-
transcriptional increase in TMEFF2 expression (71).  The post-transcriptional regulatory 
connection between androgen signaling and TMEFF2 expression was not investigated further, 
and it is not known if the increase in TMEFF2 was the result of increased translation, the 
stability of the TMEFF2 protein or mRNA, or decreased proteolysis.  It is possible that TMEFF2 
is regulated by androgens at both the transcriptional and post-transcriptional levels, and that the 
regulatory pathways controlling its expression may be altered during tumor development or 
progression.  An evaluation of the post-transcriptional regulatory mechanism(s) controlling 
TMEFF2 expression could lead to a broadened understanding of the role of androgen signaling 
in prostate tumorigenesis and potentially provide novel targets to block androgen actions. 
 
Post-transcriptional control in prostate cancer 
The deregulated expression of oncogenes and tumor suppressors at the post-
transcriptional level has been well-documented in several cancers and can occur through a 
variety of mechanisms including changes in mRNA stability, alterations in RNA-binding protein 
activity/specificity, and alterations in translation initiation efficiency (6).  In recent years, the 
expression of an abundance of genes with suspected roles in the pathogenesis of prostate cancer 
have been shown to be regulated by the AR through post-transcriptional mechanisms (77, 108), 
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indicating that the critical influence of AR signaling on prostate tumorigenesis goes beyond the 
transcriptional stimulation of AR target gene expression. 
The overexpression or increased activity of several translation initiation factors in 
prostate cancer suggests that translational control may play a pivotal role in the establishment 
and/or progression of the disease.  As the rate-limiting step in for the translation of most 
transcripts, components of the translation initiation machinery are most often deregulated in 
tumorigenesis such as the eIF4F cap-binding complex, the 43S pre-initiation complex, and 
eIF3proteins (91, 95). For instance, the translation initiation factors eIF3h and eIF4E are 
frequently upregulated in advanced prostate cancer tissue, and the expression of each of these 
proteins is associated with an aggressive disease prognosis (21).  The increased activation of 
eIF4E has also been demonstrated in prostate cancer through either its direct phosphorylation or 
through the phosphorylation and inhibition of 4EBP1 (an eIF4E inhibitory binding protein) (91).  
In fact, the translational regulator mTOR was recently shown to have a critical role driving 
prostate cancer cell invasion and metastasis by modulating 4EBP1 phosphorylation, increasing 
eIF4E availability and promoting the translation of a subset of pro-invasion genes (48).  It has 
also been reported that the activity of mTOR is modulated by DHT treatment in LNCaP prostate 
cancer cells (108), suggesting that androgen signaling can promote prostate tumor progression by 
modulating the activity of a major translational regulator.  A potential role for the translation 
initiation factor eIF2 in prostate cancer has also been proposed in light of the observation that the 
tumor suppressor function of PTEN requires the phosphorylation of eIF2α by PKR (74).  Like 
eIF4E, eIF2 is one of the main regulatory targets of translation initiation, and therefore may play 
an important role in cancer establishment or progression.  It is primarily regulated by the 
phosphorylation of its α subunit which leads to a global decrease in translation; however, some 
23 
 
transcripts can be selectively upregulated under these conditions (e.g. genes involved in cell 
survival under conditions of severe stress) (72).  At this time little is known concerning the role 
of eIF2α in tumorigenesis.  Studies in mouse models and various cancer cell lines have produced 
conflicting results regarding the role of eIF2α phosphorylation in cancer (21), in some cases it 
has demonstrated tumor suppressive effects and in other models it has been shown to promote 
tumorigenesis.  These highly contradictory results have may reflect a function for eIF2α 
phosphorylation that is dependent on the tissue type or on the stage of tumorigenesis. 
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CHAPTER 2: EXPERIMENTAL PROCEDURES 
 
Cell culture- All cell lines were obtained from the American Type Culture Collection 
unless stated otherwise.  LNCaP and 22RV1 cells were maintained in RPMI 1640 (Gibco) 
supplemented with either 10% FBS (Gemini Bio-products) or 10% charcoal-stripped serum 
(Atlantic Biologicals) for hormone starvation.  PC3 cells were obtained from Dr. D. Terrian 
(Department of Anatomy and Cell Biology, East Carolina University) and were also maintained 
in RPMI 1640.  Dihydrotestosterone, bicalutamide, and actinomycin D were purchased from 
Sigma-Aldrich.  RWPE1 cells were maintained in Keratinocyte Serum Free medium (Gibco) 
supplemented with the provided bovine pituitary extract and recombinant epidermal growth 
factor following the manufacturer’s recommendations. HEK293T cells were maintained in 
DMEM (Gibco) supplemented with 10% FBS.  TRAMP-C2 cells were a gift from Dr. L. Yang 
(Department of Internal Medicine, East Carolina University) and maintained as previously 
described (34).  A/A and wt/wt MEF cells were provided by Dr. R. Kaufman (Burnham Institute, 
La Jolla, CA) and were grown in DMEM with 10% FBS. All cell lines were incubated at 37ºC 
with 5% CO2. 
 
Generation of TMEFF2-overexpressing cell lines- 1) HEK293T cells stably 
overexpressing TMEFF2 were developed by transfecting an expression construct containing the 
full-length human TMEFF2 cDNA inserted into the pSecTag2A vector (Invitrogen) followed by 
antibiotic selection. The construct was transfected into HEK293T cells using Lipofectamine 
2000 (Invitrogen) following the manufacturer’s recommendations. 2) Inducible cell lines were 
developed using the Tet-on Tetracyclin Inducible Expression System (Clontech) following the 
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manufacturer’s instructions.  Briefly, an initial transduction introduces a constitutively expressed 
transactivator protein (rtTA) that is activated upon binding doxycyline.  Following antibiotic 
selection and expansion of resistant clones, a second transduction introduces a construct 
containing full-length TMEFF2 cDNA downstream from a promoter that is specifically 
recognized by the transactivator from the previous transduction.  TMEFF2 expression was 
induced by incubation of the cells with 250 ng/ml doxycycline for 48 hrs.  
 
Proliferation assay- Cells were seeded at 3,000-5,000 cell/well in 96-well plates. After 
incubation for the indicated times, MTT reagent (Sigma) was added at a concentration of 0.5 
mg/ml in phenol red-free RPMI containing 1% FBS. Following a 3.5 hr incubation at 37ºC, 200 
μl DMSO (Sigma) was added to each well, incubated for 15 min with rocking, and the OD 
measured at 562 nm.  
 
Apoptosis assay- To induce apoptosis, 30,000 cells/well were plated into 6-well plates 
and treated with 2 or 3 μM staurosporine (Sigma) for 24 hrs. Cells were harvested and washed 
with 1X PBS, and resuspended in 100 μl binding buffer [100 mM HEPES (pH 7.4), 140 mM 
NaCl, 5 mM CaCl2].  To stain the cells, 1 μl Annexin V-FITC reagent (BioVision) and 1 μl of a 
5 μg/ml propidium iodide solution (Invitrogen) were added to the cell suspension and incubated 
for 10 min at 4˚C.  The cell suspensions were spun down and resuspended in 400 μl binding 
buffer in 12 x 75 mm polystyrene tubes (Becton Dickinson). Cells were then analyzed by flow 
cytometry (FACScan, Becton Dickinson).  Technical assistance was provided by Mitch Harris. 
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Anchorage-independent growth- 2,500-3,500 cells were suspended in 0.35% agarose in 
DMEM containing 5% FBS. This suspension was overlaid onto a solidified layer of 0.4% 
agarose in a 60 mm plate. Fresh DMEM was maintained on top plates during a 14-21 day 
incubation, at which time the cells were stained with 0.005% crystal violet, gently washed with 
1X PBS, photographed, and counted.  
 
Invasion assays- Cell invasion was assayed using Boyden chambers containing a layer of 
matrigel (BD Biocoat; Becton Dickinson) and using NIH 3T3 conditioned medium as a 
chemoattractant. To analyze sarcosine induced invasion, TMEFF2 inducible and control RWPE1 
cells were grown in the presence of 50 μM sarcosine or alanine as a control. 48 hrs later, 
doxycycline was added to induce TMEFF2 expression and the cells were incubated for an 
additional 48 hrs. In total, the cells were grown 96 hrs in the presence of sarcosine or alanine and 
48 hrs in the presence of doxycycline (250 ng/ml) to induce TMEFF2 expression before they 
were added to the Boyden chambers. Following a 36-48 hr incubation to allow for invasion, the 
number of invading cells at the bottom side of the matrigel chamber and the number of non-
invading cells at the top of the matrigel were determined using a MTT assay and the percentage 
of the invading cells calculated from the total. Alternatively, following 48-hr incubation, cells 
adhering to the bottom of the membrane were fixed with 70% ethanol and stained with 0.1% 
crystal violet, photographed and counted in several random fields of view.  
 
Subcutaneous TRAMP-C2 Injections- TRAMP-C2 cells were incubated for 48 hrs in 
medium containing 250 ng/ml doxycycline to induce TMEFF2 expression prior to the injections.  
Following this incubation period, cells were harvested and washed once with cold PBS.  Mice 
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were anaesthetized by brief inhalation of isoflurane and hind flanks were shaven using clippers.  
2.5 x 10
6
 TMEFF2 inducible and control TRAMP-C2 cells suspended in 0.2 ml PBS were then 
subcutaneously injected into the flank of 7-8 wk. old C57BL/6 male mice using a 26 gauge 
needle.  Mice were continuously fed chow containing 200 mg/kg doxycycline (BioServe) to 
induce TMEFF2 expression during the incubation period.  Mice were sacrificed and tumors were 
then excised. Technical assistance was provided by Greg Tipton. 
 
TMEFF2 Fusion Constructs and Reporter Asssays- PCR mutagenesis was used to 
mutate the start codons of the uORFs in the TMEFF2 5’ UTR from AUG to GUG (see Table 1).  
The wild-type and mutant 5’ UTRs were inserted upstream of the Gaussia luciferase gene in the 
pCMV-GLuc vector (New England Biolabs).  For uORF analyses, cells were grown to 70-90% 
confluency in 6-well plates and transfected with 1.5 µg of each construct per well and the same 
amount of the pSeap-Control Vector II (BD Biosciences) using Lipofectamine 2000 (Invitrogen) 
and following the manufacturer’s protocol.  Cells and supernatants were collected 24 hrs post-
transfection and Gaussia luciferase levels were determined from the supernatants using the 
BioLux kit (New England Biolabs).   Seap (secreted alkaline phosphatase) levels were measured 
from the supernatants using the Great Escape Seap Chemiluminescence Kit 2.0 (Clontech 
Laboratories) for normalization.  Luminescence was measured for the Luciferase and Seap 
assays using a 20/20
n
 luminometer (Turner Biosystems).  mRNA was extracted from the cells to 
measure Gaussia luciferase transcript levels for normalization as described under the qRT-PCR 
procedures. 
For DHT-stimulated reporter assays, cells were hormone-starved for 48 hrs in phenol red-
free medium containing 10% charcoal-stripped serum (CSS) prior to stimulation with DHT. 
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Twenty-four hrs after hormone removal the cells were transfected using Fugene HD transfection 
reagent (Promega) following the manufacturer’s recommendations.  Briefly, 10 µg of each 
construct and 10 µg of pSeap-Control Vector II were diluted in serum-free RPMI along with 30 
µl Fugene HD reagent for a total volume of 500 µl.  100 µl of this transfection mix was added 
per well of a 6-well plate.  The following day, DHT or ethanol vehicle were added to fresh CSS-
RPMI and the cells were incubated for another 48 hrs prior to harvesting cells and supernatants. 
 
qRT-PCR - RNA was isolated from the cells using the RNAqueous kit (Ambion) 
following the supplied protocol.  cDNA was then synthesized using the iScript kit (BioRad 
Laboratories) using 0.25 μg of RNA as the template.  Message levels were measured using IQ 
SYBR Green Supermix and the IQ5 Real-Time PCR Detection System (BioRad Laboratories).  
mRNA levels were normalized to β-actin using the IQ5 Optical System Software (BioRad 
Laboratories).   
 
Androgen Receptor knockdown- AR expression was reduced in 22RV1 cells using the 
ON-TARGET plus SMART pool for human AR (Thermo Scientific).  Five µl of silencing RNAs 
and 7.5 µl of DharmaFECT Transfection Reagent (Thermo Scientific) were each separately 
diluted in 300 µl serum-free, phenol red-free RPMI.  After 5 min incubation, the solutions were 
combined and incubated for another 20 min at room temperature, then added to an 85% 
confluent cell monolayer in a T-25 flask containing 2.4 ml of complete, phenol red-free RPMI.  
siRNA-treated cells were then incubated for 48 hrs prior to treatments with DHT or vehicle. 
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Immunoblotting- Cell lysates were prepared with RadioImmunoPrecipitation Assay 
(RIPA) buffer [25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% Triton X-100, 1% sodium 
deoxycholate, 0.1% SDS] supplemented with 0.1 mM β-glycerophosphate and 0.5 mM sodium 
orthovanadate and protease inhibitor cocktail (Sigma).  Twenty µg of lysates were separated on 
Mini-protean TGX gels (BioRad) and transferred to PVDF membranes.  These were then 
blocked for 30 min in 5% non-fat dry milk diluted in 1X Tris-buffered saline + 0.1% Tween-20 
(TBS-T) and incubated with the primary antibody overnight at 4˚C.  Incubations with a 1:10,000 
dilution of horseradish peroxidase (HRP)-conjugated secondary antibody (Santa Cruz 
Biotechnology) were for 1 hr at room temperature.  Detection was carried out using SuperSignal 
West Pico Chemiluminescent Substrate (Thermo Scientific) for 5 min.  In some cases, blots were 
stripped with Restore PLUS Western Blot Stripping Buffer (Thermo Scientific) following the 
manufacturer’s recommendations.  Antibodies against TMEFF2, PSA, and eIF2α-P (Ser51) were 
from Abcam, eIF2α and CREB2/ATF4 antibodies were purchased from Santa Cruz 
Biotechnology, and the AR antibody was from Cell Signaling Technology. 
 
Polysome Analysis- Cell monolayers were scraped with lysis buffer [100 mmol/L KCl, 
10 mmol/L HEPES (pH 7.4), 0.5% NP40, 5 mmol/L MgCl2, 100 μg/ml cycloheximide], and 
incubated on ice for 10 mins, followed by a 5 min spin at 10,000 rpm at 4°C to pellet cellular 
debris. Equal protein concentrations of cytoplasmic extracts (1.8 mg) were then overlaid onto a 
linear sucrose gradient [15–45% (w/v) 10 mmol/L HEPES (pH 7.4), 100 mmol/L KCl, 5 mmol/L 
MgCl2] and centrifuged at 35,000 rpm for 2 hrs at 4°C in an SW41-Ti rotor without the brake. 
Using an ISCO UA-6 fractionator, fractions were collected with continuous UV monitoring at 
254 nm. Sucrose gradient fractionations were performed by Dr. V. Chappell (Department of 
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Anatomy and Cell Biology, East Carolina University). RNA was isolated from fractions using 
Trizol reagent (Ambion).   Twenty-five µg of RNA was then used for cDNA synthesis using the 
iScript kit (BioRad Laboratories).  A sample of 0.1 µg of each cDNA preparation was used to 
amplify TMEFF2, ATF4, and β-actin by PCR using the Platinum Taq HiFi DNA Polymerase 
system (Invitrogen).  PCR products were then visualized on a 1% agarose gel and band intensity 
was analyzed using the public domain NIH Image J program (developed at the U.S. National 
Institutes of Health and available at http://rsb.info.nih.gov/nih-image/). 
 
PB-TMEFF2 mouse generation and identification – The PB-TMEFF2 transgenic 
expression construct (see Ch. 5 for plasmid construction) was amplified with the PureLink 
HiPure Plamid Maxiprep Kit (Invitrogen) following the manufacturers recommendations and 
resuspended in TE buffer supplied with the kit.  The DNA was then transferred to the University 
of North Carolina at Chapel Hill Animal Models Core Facility where pronuclear injections were 
performed as previously described (49).  Tail snips of the mice produced were provided at 
weaning and the presence of the transgenic DNA was detected by PCR using the Terra PCR 
Direct Kit (Clontech Laboratories) following the supplied protocol and primers specific for the 
transgene (See figure 14(A) and Table 1).  
 
Statistical Analysis- Data are expressed as mean ±SD.  Differences were analyzed using 
paired, two-tailed t-tests. P values ≤ 0.05 (*) or ≤ 0.01 (**) were considered significant. 
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Table 1. Primers used for experimental procedures. 
 Primers used for plasmid construction or qRT-PCR detection   
 Construct name Primer sequence   *underlined sequences represent the uORF start codons 
1 pTM1234-GLuc  (wt)  5’-TAGGATCCCTCCACCCTGCCTCCTCG 
5’-TAACTAGTTCGTGCAACTCTGCAGCAG 
2 pTMX234-GLuc  5’-GCTGCTGCCACAAGGAGGGAGC 
5’-GCTCCCTCCTTGTGGCAGCAGC  
3 pTM1X34-GLuc  5’-GAGTTTCAGCAACACCCAGGGACT 
5’-AGTCCCTGGGTGTTGCTGAAACTC  
4 pTM12X4-GLuc 5’-CCCGCGCACGATGTCGAGAG 
5’-CTCTCGAGATCGTGCGCGGG 
5 pTM123X-GLuc 5’-GCTACTGAGCACCCCGCGGAC 
5’-GTCCGCGGGGTGCTCAGTAGC  
6 TMEFF2 5’-TCTTGCAGGTGTGATGCTGG 
5’-GCTCCCTTTAGATTAACCTCG 
7 β-actin  5’-GGACTTCGAGCAAGAGATGG 
5’-AGCACTGTGTTGGCGTACAG  
8 ATF4  5’-TCAAACCTCATGGGTTCTCC                      
5’-GTGTCATCCAACGTGGTCAG 
9 Gaussia luciferase  5’-GGAGGTGCTCAAAGAGATGG 
5’-TTGAACCCAGGAATCTCAGG  
 Primers used for genotyping transgenic mice by PCR  
10 PB-TMEFF2 5’-CAGGGCACTACAGTTCGACA  
5’-CAAATGTGGTATGGCTGATTATG 
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CHAPTER 3 
 
TMEFF2 FUNCTIONS AS A TUMOR SUPPRESSOR IN PROSTATE CANCER CELLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Adapted from Xiaofei Chen, Ryan Overcash, Thomas Green, Donald Hoffman , Adam 
Asch and Maria J. Ruiz-Echevarría. (2011) J Biol Chem 286(18), 16091–16100 ((17)) 
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Introduction 
 
TMEFF2 is an evolutionarily conserved type I transmembrane protein expressed in the 
embryo (99) and selectively in the adult brain and prostate (35, 39).  It is expressed in several 
regions of the brain, and overexpression of the TMEFF2 ectodomain has been demonstrated to 
promote survival in primary neurons (47).  A critical role for this protein in tumorigenesis is 
suggested by the fact that it is upregulated in a significant fraction of primary and metastatic 
prostate tumors (35, 39, 71).  It has been suggested that TMEFF2 may function as a tumor 
suppressor because ectopic expression of full-length TMEFF2 demonstrates anti-growth effects 
in vitro and suppresses tumor growth in nude mouse xenografts (27, 35). Consistent with a tumor 
suppressor function, TMEFF2 has been shown to be hypermethylated in a number of cancer 
types (41, 62) and the TMEFF2 promoter is repressed by c-Myc (37).    
The present study expands our understanding of the role of TMEFF2 in tumorigenesis.  
For this purpose, we overexpressed TMEFF2 in HEK293T cells and RWPE1 prostate epithelial 
cells and assessed the effects on specific traits that are hallmarks of a cancerous phenotype.  
These traits include elevated proliferation rates, invasion, survival, and anchorage-independent 
growth capabilities.  We show that the ectopic expression of full-length TMEFF2 results in 
monolayer and anchorage-independent growth inhibition in HEK293T cells.  Additionally, 
although TMEFF2 overexpression alone did not induce apoptosis, it resulted in a marked 
increase in apoptotic cells after the chemical induction of apoptosis with staurosporine, 
demonstrating that it can sensitize cells to undergo the apoptotic program.  To evaluate the 
effects of TMEFF2 overexpression on prostate cell invasion we incubated RWPE1 cells with the 
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metabolite sarcosine, a proposed prostate cancer biomarker that promotes cell invasion (93), and 
demonstrate that TMEFF2 overexpression blocks RWPE1 cell invasion.  No significant 
impairment of proliferation was observed as a result of TMEFF2 overexpression in these cells. 
These results collectively indicate that TMEFF2 functions as a tumor suppressor.   
In order to test the tumor suppressor activity of TMEFF2 in vivo, we generated TRAMP-
C2 murine prostate cancer cells that are inducible for TMEFF2 expression and subcutaneously 
injected the cells into syngeneic male mice. The induction of TMEFF2 expression significantly 
inhibited the ability of the TRAMP-C2 cells to form tumors relative to cells that did not express 
TMEFF2. 
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Results 
 
Increased expression of TMEFF2 inhibits cell growth in HEK293T cells 
To investigate the function of TMEFF2 in tumorigenesis, we first determined whether 
ectopic expression of this protein could affect cellular proliferation. HEK293T cells stably 
expressing untagged (TMEFF2-wt) or c-Myc-His-tagged (TMEFF2-Myc-His) TMEFF2 
proteins, along with control cells transfected with empty vector or untransfected cells, were 
generated for this purpose. Overexpression of either untagged (Fig. 5A) or C-terminal c-Myc-
His-tagged TMEFF2 (not shown) in HEK293T cells decreased cell numbers by 20–30% with 
respect to the untransfected cells or the cells transfected with the empty vector. The presence of 
the C-terminal c-Myc-His tag did not change the effect of TMEFF2 on cell growth. Therefore, 
subsequent experiments were done using the c-Myc-His-tagged form of the protein.  
To further characterize the nature of TMEFF2 overexpression on cell tumorigenicity, 
FACS analysis was used to investigate the effect of TMEFF2 on apoptosis. HEK293T cells 
stably transfected with TMEFF2-Myc-His or with the empty vector as a control were induced to 
undergo apoptosis with staurosporine, a protein kinase inhibitor that triggers both caspase-
dependent and caspase-independent apoptotic pathways (10). Overexpression of TMEFF2 on its 
own had no effect on the number of apoptotic cells in HEK293T cells. However, it increased the 
sensitivity of the cells to staurosporine-induced apoptosis when compared with empty vector 
transfected cells (Fig. 5, B and C). The observed effects of TMEFF2 overexpression on 
proliferation rates are consistent with a role as a tumor suppressor. 
Most normal mammalian cells require adhesion to the extracellular matrix to grow and 
survive; however, in the course of tumor progression, cancer cells often lose this requirement and 
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acquire anchorage-independent growth capabilities.  This feature is particularly important for the 
spread of tumor cells outside of the primary tumor and in the metastatic dissemination of cancer 
cells.  To investigate the tumor suppressor potential of TMEFF2, we assessed its ability to 
promote anchorage-independent growth using a soft agar growth assay. HEK293T cells stably 
expressing TMEFF2-Myc-His formed ∼5-fold fewer colonies, which were of smaller size than 
cells carrying the empty vector (Fig. 5, D and E). Thus, TMEFF2 suppresses the formation and 
the growth of HEK293T colonies in soft agar. Overexpression of TMEFF2 had no effect on the 
migration or invasion ability of HEK293T cells as measured using Boyden chambers (not 
shown).  
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FIGURE 5.  TMEFF2 inhibits proliferation and anchorage-independent growth and 
sensitizes cells to apoptosis.  (A) Stable expression of TMEFF2 decreases proliferation of 
HEK293T cells, (B and C) sensitizes the cell to an apoptotic stimulus, and (D and E) inhibits 
anchorage-independent growth.  Overexpression of TMEFF2 was confirmed by western blot 
analysis (A insets). The effect of TMEFF2 on growth (A) was determined using an MTT assay 
after 96 h of growth. The A562 at 96 h was normalized first to the value obtained at zero time (to 
correct for plating variability) and then to the value obtained for the parental cell line 
(HEK293T; A). The effect of TMEFF2 on apoptosis in HEK293T cells (B and C) was 
B C 
D E 
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determined in the presence of staurosporine or the vehicle, as a control, by analyzing the number 
of annexin V-positive cells and comparing it with the numbers obtained when expressing the 
empty vector.  B and C, a representative image of the flow cytometry analysis (B) and percentage 
of apoptotic cells (C).  D and E, a representative image showing anchorage-independent growth 
(D) and the number of colonies formed by HEK293T cells stably expressing TMEFF2-Myc-His 
or the empty vector as a control (E) after 14 days of growth. Data shown are mean ± S.D. of at 
least three independent experiments with multiple replicates. Several clones were tested to rule 
out that the effects are due to the insertion site. *, p < 0.05, and **, p < 0.01. 
 
*This research was originally published in the Journal of Biological Chemistry. Chen, X., 
Overcash, R., Green, T., Hoffman, D., Asch, A., MJ Ruiz-Echevarria. The tumor suppressor 
activity of the transmembrane protein with epidermal growth factor and two follistatin motifs 2 
(TMEFF2) correlates with its ability to modulate sarcosine levels. J Biol Chemistry. 2011; 
286:16091-16100. © the American Society for Biochemistry and Molecular Biology. 
 
 
 
TMEFF2 Inhibits Sarcosine-induced Cell Invasion of Prostate Epithelial Cells 
Because the expression of TMEFF2 is mainly restricted to brain and prostate, we sought 
to analyze the effect of TMEFF2 overexpression in prostate cells. We selected RWPE1 cells, 
derived from non-neoplastic human prostatic epithelial cells (9), which express very low levels 
of endogenous TMEFF2 as demonstrated by quantitative RT-PCR (not shown). Full-length 
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TMEFF2 was introduced into the RWPE1 cells by retroviral gene transfer to generate an RWPE1 
cell line that inducibly expresses TMEFF2 with the addition of doxycycline to the growth 
medium (RWPE1-TMEFF2i). Control cells were transduced with the transactivator construct 
only (RWPE1-tet).  High levels of TMEFF2 expression in the RWPE1-TMEFF2i cell line upon 
the addition of doxycycline was demonstrated (Fig. 6A). To test whether TMEFF2 affects the 
growth rate of RWPE1 cells, RWPE1-TMEFF2i cells were grown in the absence (no TMEFF2 
expression) and presence (TMEFF2 expression) of doxycycline, and the effect of TMEFF2 on 
the growth rate was determined. No significant effect of TMEFF2 on the growth rate of RWPE1 
cells was observed when compared with the RWPE1-tet cells (Fig. 6B).  
The invasion of prostate cancer cells across the basement membrane and eventually to 
extra-prostatic tissue is a critical tumorigenic program leading the way to metastasis.  We 
therefore tested the effects of TMEFF2 overexpression on the invasive capability of RWPE1 
cells.  As mentioned, sarcosine is a proposed marker for prostate cancer progression and the 
addition of sarcosine to RWPE1 cells increases the invasive capability of the cells (93).  We 
therefore tested whether TMEFF2 can reverse sarcosine-induced invasion. Briefly, RWPE1-
TMEFF2i cells were grown in the presence of sarcosine to induce invasion and doxycycline to 
induce TMEFF2 expression.  Alanine was used as a control for sarcosine-induced invasion.  The 
invasive potential was then analyzed using Boyden chambers containing a thin layer of matrigel 
to simulate a basement membrane. The effect of TMEFF2 was investigated by comparing the 
invasion of RWPE1-TMEFF2i cells with the invasive ability of the control cell line, RWPE1-tet, 
both in the presence of doxycycline.  As expected, the addition of sarcosine resulted in an 
increase in the invasion of the RWPE1-tet cells (Fig. 6C) when compared with cells grown in the 
presence of alanine. Overexpressing TMEFF2 in these cells reduced cell invasion both in the 
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control (alanine-treated) cells and to a greater extent in the cells treated with sarcosine (Fig. 6C). 
These results suggest that TMEFF2 can block the intrinsic and the sarcosine-induced invasive 
potential of RWPE1 cells. It is worth noting that although in HEK293T cells TMEFF2 
negatively affects cell growth but has no effect on migration or invasion (data not shown), it has 
no effect on cell growth in RWPE cells while it substantially reduces invasion, indicative of the 
cell line-specific effect of TMEFF2.  
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Figure 6.  TMEFF2 inhibits invasion in RWPE cells. (A) Western blot demonstrating the 
induction of TMEFF2 expression in response to doxycycline (Dox, 250 ng/ml) in the RWPE1-
TMEFF2i cell line. β-Tubulin was used as loading control.  (B)  The effect of TMEFF2 
overexpression on the growth of RWPE1 cells was determined using an MTT assay after 96 h of 
growth. The A560 at 96 h was normalized first to the value obtained at zero time (to correct for 
plating variability) and then to the value obtained for same cells grown in the absence of 
doxycycline (no TMEFF2 expression). (C) The effect of TMEFF2 overexpression on the 
invasion ability of RWPE1 cells was determined using a MTT-based modified Boyden chamber 
assay. RWPE1-TMEFF2i or RWPE1-tet cells were grown for 96 hours in the presence of 50 μM 
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alanine or sarcosine and for 48 hours in the presence of doxycycline (250 ng/ml) and then added 
to the Boyden chambers and allowed to invade for 48 hrs.  The number of invading cells at the 
bottom side of the matrigel chamber and the number of non-invading cells at the top of the 
matrigel were determined using a MTT assay and the percentage of the invading cells calculated 
from the total. Invasive cells from a random experimental repeat were visualized by fixing the 
cells adhering to the bottom of the membrane with 70% ethanol and staining with 0.1% crystal 
violet. Cells were then photographed (bottom). 
*This research was originally published in the Journal of Biological Chemistry. Chen, X., 
Overcash, R., Green, T., Hoffman, D., Asch, A., MJ Ruiz-Echevarria. The tumor suppressor 
activity of the transmembrane protein with epidermal growth factor and two follistatin motifs 2 
(TMEFF2) correlates with its ability to modulate sarcosine levels. J Biol Chemistry. 2011; 
286:16091-16100. © the American Society for Biochemistry and Molecular Biology. 
 
 
TMEFF2 inhibits TRAMP-C2 tumor growth in vivo 
The tumor suppressor activity of TMEFF2 was next evaluated in vivo using a TRAMP-
C2 allograft model.  The TRAMP-C2 cell line was derived from a prostate tumor in a transgenic 
adenocarcinoma of the mouse prostate (TRAMP) mouse model.  These mice develop prostate 
tumors as a result of the prostate-specific expression of the SV40 T antigen in C57BL/6 mice. 
The TRAMP-C2 cells have an epithelial origin and are tumorigenic when injected into syngeneic 
mice (34).  As described for the inducible RWPE1 cells, we developed TRAMP-C2 cells that are 
inducible for TMEFF2 expression with the addition of doxycycline.  To establish subcutaneous 
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TRAMP-C2 tumors, cells were incubated in doxycycline for 48 hrs, collected, and 2.5 X 10
6
 
inducible or non-inducible (vector-only) cells were injected into the flank of 7-8 wk. old male 
C57BL/6 mice and monitored for tumor growth.   Our results demonstrate that overexpression of 
TMEFF2 significantly inhibited TRAMP-C2 tumor development, with only 12.5% of mice that 
developed tumors when injected with inducible TRAMP-C2 cells while 62.5% of mice injected 
with vector-only cells developed tumors (Fig. 7).  It is important to note that we were unable to 
detect TMEFF2 protein expression in any of the tumors that developed following the injection of 
inducible TRAMP-C2 cells despite being continuously supplied doxycycline to maintain 
TMEFF2 expression.  It is not clear why the cells in these tumors did not express TMEFF2; 
however, it is possible that some TRAMP-C2 cells with low or no TMEFF2 inducibility had a 
growth or survival advantage and outgrew the cells expressing TMEFF2. 
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Figure 7. TMEFF2 inhibits TRAMP-C2 tumor growth in vivo. Bars represent the percentage 
of mice that developed subcutaneous tumors out of 16 mice injected with TRAMP-C2 cells per 
condition.  Mice were injected with TRAMP-C2 cells that are inducible for TMEFF2 expression 
or cells carrying the vector only, and continuously fed a diet containing 200 mg/kg doxycycline 
to maintain TMEFF2 expression. 
 
 
 
  n=16 
each 
p=0.0035 
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Discussion 
 
The upregulation of TMEFF2 expression in primary and metastatic prostate cancers 
relative to benign prostate tissue suggests a role for the gene in the establishment and/or 
progression of prostate cancer.  To date, however, functional studies have not established a clear 
role for TMEFF2 in prostate tumorigenesis as many of these studies have produced conflicting 
results.  Part of the discrepancy from previous reports may be due to the evaluation of TMEFF2 
function in cells from several different cancer types or tissues, which has demonstrated cell-type-
specific effects of its function.   Furthermore, the structural features of the TMEFF2 protein give 
it the potential to influence a variety of pathways or cellular processes.  For example, the 
follistatin domains of TMEFF2 are generally known to bind and inactivate members of the TGF-
β signaling pathway; however, the effects of TGF-β signaling can be diverse and its role in 
cancer is dependent on the stage or specific genetic aberration(s) driving the cancer, sometimes 
tumor suppressive and sometimes oncogenic (2).  The presence of a putative G-protein activating 
motif at the C-terminus of TMEFF2 suggests a potential role in second messenger signaling 
through G-proteins, a class of membrane proteins with diverse cellular effects that has been 
implicated in driving several tumorigenic processes including hormone-independence, 
inflammation, and metaststasis (25).  Additionally, the cleavage and release of TMEFF2 from the 
membrane by ADAM proteins may be a critical regulated step in influencing the biological role 
of TMEFF2 as the regulated cleavage or “shedding” of ectodomains has been documented to 
play an important role cancer progression.  Ectodomain shedding is critical for the activation of 
many growth factors in cancer and in some cases can produce proteins with functions that 
oppose the membrane-bound form (84).   Altogether, the functional studies to date suggest a 
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complex biological function for TMEFF2 that may be largely dependent on its environment or 
other cell-type-dependent factors. 
Here we evaluate the functional role of TMEFF2 in tumorigenesis and assess its 
influence on several phenotypic traits that are hallmarks of cancer cells.  We show that the full-
length TMEFF2 functions as a tumor suppressor capable of inhibiting cell proliferation and 
invasion, antagonizing survival, and severely blocking anchorage-independent growth.  
Consistent with previous observations, our results show some differences in the specific tumor 
suppressive effects of TMEFF2 in different cell lines.  For instance, ectopic TMEFF2 expression 
reduced proliferation rates in HEK293T cells but had no effect on proliferation in RWPE-1 cells.  
Similarly, while TMEFF2 overexpression strongly inhibited RWPE-1 cell invasion, it had no 
effect on HEK293T cell invasion.  Despite the cell-type-specific effects, TMEFF2 clearly 
demonstrated tumor suppressor activity in each of the cell lines examined.  Confirming its tumor 
suppressor function in vivo, the subcutaneous development of TRAMP-C2 tumors was 
significantly inhibited as a result of TMEFF2 overexpression.    
The functional assays presented here provide insight into the potential effects of TMEFF2 
tumor suppression in prostate tumorigenesis.  Results from the phenotypic assays demonstrate 
that TMEFF2 is capable of influencing multiple hallmark tumorigenic traits, and therefore has 
the potential to influence prostate cancer progression at multiple levels/stages. Interestingly, 
some of the most profound effects of TMEFF2 overexpression from the in vitro analysis of 
TMEFF2 function were the inhibition of cell invasion and a substantial inhibition of anchorage-
independent growth.  These features are critical components of the metastatic spread of cancer 
cells, and the inhibition of these traits by TMEFF2 suggests a possible role in the suppression of 
metastasis.  However, in contrast to most of the current established “metastasis suppressor 
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genes”, TMEFF2 is also capable of inhibiting cell proliferation and can therefore effect tumor 
growth in the earlier stages as well.  Additionally, our results show that TMEFF2 overexpression 
has a negative effect on cell survival in the presence of an external apoptotic stimulus but does 
not induce apoptosis on its own.  Therefore, in the stressful microenvironment of a tumor or in a 
cell attempting to colonize a foreign site, the sensitization of apoptotic signaling pathways may 
also represent an important mechanism by which TMEFF2 functions.  The propensity of 
TMEFF2 to inhibit the development of tumors in the TRAMP-C2 allograft model as opposed to 
influencing tumor size may reflect its ability to antagonize tumor cell colonization/survival in a 
foreign environment. 
 Although our results clearly demonstrate a tumor suppressor function, we cannot deduce 
from these results that TMEFF2 always functions to suppress tumor growth within the 
environment of a tumor, where conditions surrounding the cancer cells are inundated with 
mitogens, inflammatory cytokines, and overactive oncogenic signaling pathways (23).  As 
previously mentioned, the ectopic expression of the TMEFF2 ectodomain has been shown to 
exert pro-growth effects (5, 17), and its cleavage is stimulated by pro-inflammatory cytokines 
including IL-1β and TNF-α (65).  It is therefore conceivable that TMEFF2 can exert either a 
tumor suppressive or tumor-promoting role in cancer that is dependent on signals from the tumor 
environment.  A complete understanding of the role of TMEFF2 in prostate tumorigenesis will 
require an evaluation of the effects of its overexpression in a mammalian model of prostate 
cancer. 
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CHAPTER 4 
 
ANDROGEN SIGNALING PROMOTES TRANSLATION OF TMEFF2 IN PROSTATE 
CANCER CELLS VIA THE PHOSPHORYLATION OF THE α SUBUNIT OF THE 
TRANSLATION INITIATION FACTOR 2 (eIF2α) 
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Introduction 
 
 Androgens signaling through the AR play an essential role in normal prostate 
development and contribute to the progression of prostate cancer. Binding of androgens to the 
AR promotes a conformational change that ultimately leads to its translocation to the nucleus and 
regulation of transcription of a specific set of androgen-responsive genes. Clinical and 
experimental evidence suggest that prostate cancer progression occurs through alteration of the 
normal androgen signaling, reducing the specificity or the amount of AR ligand required for 
proliferation and survival (8). Importantly, recent results indicate that the function of the AR is 
specific to the disease stage, triggering a different gene expression program in androgen-
dependent as compared to androgen-independent prostate cancer (104). While the role of the AR 
signaling axis in transcriptional regulation is well documented, very little is known regarding its 
role in translation initiation proposed in early studies (63, 64).  
 As previously mentioned, TMEFF2 is expressed in the embryo (99) and selectively in the 
adult brain and prostate (3, 35, 39).  A role for TMEFF2 in prostate cancer was suggested by 
studies indicating that TMEFF2 expression is altered in a significant fraction of primary and 
metastatic prostate tumors (3, 35, 39, 71).  In addition, we recently demonstrated that TMEFF2 
interacts with sarcosine dehydrogenase (SARDH), the enzyme responsible for conversion of 
sarcosine to glycine (17). Importantly, sarcosine was identified as a marker for prostate cancer 
progression in a large-scale screen of metabolites from human prostate samples (93).  Increased 
plasma and urine sarcosine levels distinguished prostate cancer from benign prostate tissue, and 
were further elevated in metastatic cancer. In addition, sarcosine metabolism and the enzymes 
involved in it (i.e. SARDH) were shown to act as regulators of cell invasion and metastasis (93). 
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Therefore, the interaction of TMEFF2 with SARDH further suggests a role for TMEFF2 in 
prostate cancer progression. In fact, we have also established that full-length TMEFF2 functions 
as a tumor suppressor and that this role correlates, at least in part, with its ability to interact with 
SARDH and modulate the cellular levels of sarcosine (17).  In this study we report that 
translation of TMEFF2 is regulated by androgens, and this effect requires a functional AR.  
Results using xenograft models and prostate cancer cell lines established that TMEFF2 
expression changes in response to androgens and/or the androgen-dependent or -independent 
condition of the cells (35, 71). As demonstrated by Gery et al., (35) these changes are in part due 
to transcriptional activation of TMEFF2 in response to androgens. However, increased TMEFF2 
protein levels in the absence of a corresponding increase in mRNA levels have been observed 
after addition of androgens to castrated animals carrying CWR22 xenografts, suggesting that 
TMEFF2 may also be post-transcriptionally regulated (71). 
 The TMEFF2 mRNA has several potential upstream open reading frames (uORFs) in its 
leader region, and sequence analysis suggests that they are well conserved among mammals. 
Although only present in 5-10% of the cellular mRNAs, uORFs are common in the leader 
regions of mRNAs encoding oncoproteins or proteins involved in the control of cellular growth 
and differentiation, and they function by modulating translation of these essential genes (72) . 
After being translated, uORFs generally block translation of the main downstream coding region 
by hampering translation reinitiation at the main translation initiation codon. However, uORFs 
can promote selective translation of the downstream coding region under cellular stress or other 
conditions that increase phosphorylation of the α subunit of the eukaryotic translation initiation 
factor 2 (eIF2α) (72). 
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 eIF2 in its GTP-bound form is required for the selection of the translation initiation 
codon. Phosphorylation of the α subunit of eIF2 at Ser-51 (eIF2α-P) inhibits the exchange of 
eIF2-GDP to eIF2-GTP, preventing recognition of the initiating codon and decreasing global 
translation initiation (96). However, as mentioned above, uORF-containing mRNAs are actively 
translated under these conditions. Two mechanisms have been proposed to explain this effect. In 
the first one, exemplified by the ATF4 mRNA that contains two uORFs, translation reinitiation at 
the inhibitory downstream uORF is bypassed under conditions of eIF2α-P, due to the fact that 
the lower levels eIF2-GTP increase the time required for the scanning ribosomes to re-acquire 
eIF2-GTP and reinitiate translation (103). In the second one, observed in mRNAs containing a 
single uORF, scanning ribosomes bypass the inhibitory uORF due to the reduced efficiency of 
translation at initiation codons with a poor Kozak consensus sequence (79). In both cases, the 
uORF bypass results in an increased number of ribosomes starting translation at the initiation 
codon of the main coding sequence, thereby increasing synthesis of that specific protein.  
In this study, we demonstrate that TMEFF2 translation is regulated by androgens. 
Androgen-regulation of TMEFF2 translation requires the presence of the uORFs in the leader 
region of the TMEFF2 mRNA and is dependent on eIF2α-P. Further, this effect is mediated by 
the AR since it is not observed when AR levels are reduced by RNAi or the antagonist 
bicalutamide, or in cell lines that do not express it.  These results support a novel regulatory 
mechanism of androgen signaling in which uORF-containing mRNAs are translationally 
activated in response to eIF2α-P.   
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Results 
 
The TMEFF2 5’-UTR contains several uORFs that block translation of the TMEFF2 
protein  
  The 5’ UTR of the TMEFF2 mRNA contains several potential uORFs (Fig. 8A) that, if 
translated would potentially block translation of the TMEFF2 main coding sequence, and 
therefore contribute to the regulation of TMEFF2 expression. To investigate the role of the 
uORFs in regulating TMEFF2 protein expression, we determined whether blocking translation of 
the uORFs would affect translation of the TMEFF2 protein in human prostate cancer cell lines. A 
TMEFF2-Gaussia Luciferase (GLuc) reporter was generated for this purpose by cloning the 
TMEFF2 5’-UTR, including four uORFs, upstream of the GLuc sequences (pTM1234-Gluc; 
Figure 8B). The TMEFF2-Gluc fusion was placed under control of the CMV promoter. The 
regulatory contribution of the uORFs to TMEFF2 translation was evaluated by mutating the start 
codons (AUGs) of the four potential uORFs (AUG to GUG, Fig. 8B) and determining their 
effect on GLuc expression in the androgen-dependent prostate cancer cell line LNCaP and its 
bone-metastatic, androgen-independent derivative C4-2B cell line. A six- to seven-fold increase 
in Luciferase expression was observed when the AUGs from all four uORFs were mutated 
(pTMXXXX-Gluc; Fig. 8C). Single mutations on the AUGs of the second, third or fourth uORFs 
promoted a 3-4 fold increase in GLuc expression, while mutating the AUG of the first uORF had 
a very small effect, suggesting a minimal role, if any, in regulation of TMEFF2 expression. 
Accordingly, combined mutations of uORFs 2, 3, and 4 resulted in a five- to six-fold increase in 
Luciferase expression of the reporter, similar to that observed when all four uORFs were mutated 
(Fig. 8C). Similar results were obtained in other androgen-responsive (22Rv1) and -independent 
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(PC3) prostate cancer cell lines. Mutation of the uORFs resulted in increased Luciferase 
expression of the GLuc reporter, albeit at variable fold induction (Fig. 8D). In the constructs used 
for these experiments, expression of the fusion gene was directed by the CMV promoter, and the 
luciferase activity was normalized to mRNA levels. Altogether, these results suggest that the 
uORFs in the 5’- UTR of TMEFF2 mRNA function synergistically to repress translation of the 
main downstream ORF.  
 
 
 
 
 
 
54 
 
21 aa
59 aa
28 aa
26 aa
AUG 5’ 
21 aa
59 aa
28 aa
26 aa
pTM1234-Gluc G-Luc
pTMX234-Gluc
pTM1X34-Gluc
pTM12X4-Gluc
pTM123X-Gluc
X
X
X
X
G-LucpTM1XXX-Gluc
X
X X
G-LucpTMXXXX-Gluc X X X
B
C D
0
1
2
3
4
5
6
7
8
9
N
o
rm
a
liz
e
d
 L
u
c
if
e
ra
s
e
a
c
tiv
it
y
(f
o
ld
 o
f 
w
t 
5
'-
U
T
R
)
Construct
LNCaP C4-2B
**
*
** **
**
**
0
2
4
6
8
10
12
14
pTM1234 pTMXXXX
L
u
c
if
e
ra
s
e
/S
E
A
P
 a
c
tiv
it
y 
(f
o
ld
 o
f 
w
t 
5
'-
U
T
R
)
Construct
PC3
22Rv1
AUG            GUG
21 aa X
A
1
 
Figure 8. The uORFs in the 5’-UTR of TMEFF2 inhibit translation of the main coding 
region.  A) Schematic representation of 394 nt upstream of the TMEFF2 main coding region and 
relative localization of four potential uORFs (aa = amino acid) within the 5’-UTR. B) Schematic 
representation of the TMEFF2-Gaussia Luciferase reporter and mutant constructs. The X 
indicates mutation of the AUG to a GUG to prevent translation of the mutated uORFs. Single 
and multiple mutations were introduced. C) Luciferase activity demonstrated by the pTM1234-
Gluc and the different mutant constructs in LNCaP and C4-2 cells. D) Luciferase activity 
demonstrated by the pTM1234-Gluc and multiple mutant construct with all the uORFs mutated 
(pTMXXXX-Gluc) in PC3 and 22Rv1 cells. In C) and D), luciferase activity was measured in 
the supernatant and calculated by first normalizing to mRNA levels for each construct and then 
to the luciferase activity demonstrated by the pTM1234-Gluc reporter construct, which does not 
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have mutations in the uORFs, considered arbitrarily as 1. Data shown are mean ± S.D. of at least 
two independent experiments with multiple replicates. *, p < 0.05, and **, p < 0.01. 
 
 
 
Translation of the TMEFF2-Luciferase reporter is regulated by androgens through a 
mechanism that requires the presence of the uORFs in the mRNA leader region 
TMEFF2 transcription is regulated by androgens (35). However, it has been suggested 
that androgens also affect TMEFF2 expression at the post-transcriptional level (71), prompting 
us to examine whether TMEFF2 translation was affected by androgens. 22Rv1 cells were 
selected for these experiments since: i) they have been shown to be a valuable model for AR-
mediated reporter gene assays (53), ii) they demonstrated the highest fold increase in Luciferase 
reporter gene expression when the uORFs were mutated (see Fig. 8D), and iii) they express 
detectable levels of endogenous TMEFF2. 22Rv1 cells were transfected with the pTM1234-Gluc 
reporter, grown in phenol red-free media supplemented with charcoal-stripped  serum (CSS) -- to 
remove steroid hormones- and treated with different concentrations of dihydrotestosterone 
(DHT). Luciferase activity was measured from the supernatants and normalized to mRNA levels. 
Addition of DHT increased luciferase expression in a dose-dependent manner (Fig. 9A), 
indicating that androgens stimulate the translation of the main ORF. Importantly, this effect was 
observed at DHT concentrations within the physiological levels found in human serum (30).  
Luciferase activity from cells carrying the pTMXXXX-Gluc reporter construct, in which the 
AUGs from all four uORFs were mutated, did not change in response to DHT, although, as 
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expected, was much higher (Fig. 9A). These results indicate that translation of the main ORF 
downstream of the TMEFF2 5’- UTR is regulated by androgens in an uORF-dependent manner.  
 To determine whether the DHT effect on translation is mediated by the AR, the 
experiments described above were repeated in the presence of bicalutamide to block AR 
activation. Addition of this drug reduced the DHT-mediated induction of the pTM1234-Gluc 
reporter luciferase expression to near basal levels, although a small two- to three-fold induction 
could be observed at 10 nM DHT (Fig. 9B).  These results indicate that the effect of DHT on 
translation of the reporter construct requires AR signaling.  Confirming these results, we did not 
observe DHT-induced translation of the pTM1234-Gluc reporter in PC3 prostate cancer cells that 
do not express the AR (Fig. 9C). Altogether, these results suggest that DHT-induced translation 
of TMEFF2 requires activation of the AR and is mediated by the uORFs in the leader region of 
the TMEFF2 mRNA. 
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Figure 9.  DHT promotes AR-mediated increased translation of the TMEFF2-GLuc fusion 
protein in 22Rv1 prostate cancer cells. A) Luciferase activity demonstrated by the pTM1234-
Gluc and the pTMXXXX-Gluc mutant construct in 22Rv1 cells in the presence of different 
concentrations of DHT. B) Luciferase activity demonstrated by the pTM1234-Gluc construct in 
22Rv1 cells in the presence of different concentrations of DHT and DHT + 20 µM bicalutamide 
(Bic). C) Luciferase activity demonstrated by the pTM1234-Gluc construct in PC3 cells in the 
presence of different concentrations of DHT. For all these experiments cells were hormone-
starved in phenol red-free media containing charcoal-stripped serum. Luciferase activity was 
normalized to mRNA levels for each construct and then to the luciferase activity demonstrated 
by each one of the constructs expressed in cells grown in the absence of DHT, which was set to 
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1. Data shown are mean ± S.D. of at least three independent experiments with multiple 
replicates. *, p < 0.05, and **, p < 0.01. 
 
 
 
Translation of the endogenous TMEFF2 protein is regulated by androgens 
Changes in the expression of the endogenous TMEFF2 protein in response to androgens 
were also analyzed. For this purpose, 22Rv1 cells were grown in phenol red-free media 
supplemented with CSS, treated with different concentrations of DHT and lysates analyzed for 
TMEFF2 expression by western blotting. In the absence of androgens, expression of TMEFF2 
was barely detectable.  However, addition of DHT increased TMEFF2 expression (Fig.10A), and 
resulted in the highest levels within the range of physiological DHT concentrations.  DHT-
induced expression of endogenous TMEFF2 was also observed in the androgen-responsive 
prostate cancer LNCaP cells (Fig. 10A). The expression of prostate specific androgen (PSA), an 
AR target used as control for androgen transcriptional activity, was enhanced by the addition of 
DHT (Fig. 10A). Treatment of the cells with bicalutamide notably inhibited DHT-induced 
TMEFF2 and PSA expression that was only observed at the highest concentrations of DHT (Fig. 
10A). Inhibition of DHT-induced TMEFF2 expression was also achieved after knocking down 
expression of the AR using siRNA (Fig. 10B). Altogether, these results indicate that the 
expression of the endogenous TMEFF2 protein is regulated by AR signaling.   
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Figure 10.  DHT promotes AR-mediated increased expression of the endogenous TMEFF2 
protein in 22Rv1 and LNCaP prostate cancer cells. A)  Representative western blots 
indicating an increase in TMEFF2 expression in response to DHT addition in 22Rv1 and LNCaP 
cells. Simultaneous addition of 20 µM bicalutamide to 22Rv1 cells (middle panel) prevented the 
increase in TMEFF2 expression observed at physiological concentration of DHT.  PSA was used 
as positive control since its expression is induced by androgen in an AR-dependent manner. β-
tubulin was used as a loading control. B) Western blot indicating effective knock down of the 
two forms of the AR in 22Rv1 cells using siRNA (left). Representative western blot indicating 
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that addition of DHT has no effect on the expression of TMEFF2 in cells in which AR levels 
were reduced by RNAi. PSA was used as control and, as expected, its expression was not 
affected by DHT in the AR-siRNA treated cells. β-tubulin was used as a loading control. C) 
Changes in TMEFF2 mRNA level in LNCaP and 22Rv1 cell lines in response to DHT as 
measured by qRT-PCR. Values were normalized to β-tubulin mRNA. Each experiment was 
repeated at least three times and, for the representative images presented, the membranes were 
stripped and re-probed with the different antibodies or the same samples were re-run in a 
β-tubulin was used as a loading control each time the samples were run.  
 
 
   
Androgen signaling promotes eIF2α phosphorylation 
Phosphorylation of eIF2α reduces global translation but also provides a mechanism that 
selectively enhances translation of uORF-containing mRNAs (72). We therefore hypothesized 
that the molecular mechanism by which DHT promotes endogenous TMEFF2 translation was 
through the phosphorylation of eIF2α. The effect of DHT on eIF2α phosphorylation was 
examined by western blot analysis in prostate cancer 22Rv1 and PC3 cells grown in phenol red-
free media supplemented with CSS and treated with different concentrations of DHT. Increased 
levels of eIF2α-P were clearly detected, in a dose-dependent manner, in lysates from DHT-
treated 22Rv1 cells but not in lysates from DHT-treated AR-null PC3 cells (Fig. 11A), indicating 
that androgens promote eIF2α-P and that this effect is dependent on the presence of a functional 
AR. Confirming these results, pretreatment of the 22Rv1 cells with the AR antagonist 
bicalutamide prevented DHT-mediated increases in eIF2α phosphorylation (Fig. 11B). DHT 
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addition also promoted an increase in the expression of the ATF4 protein, a transcription factor 
regulated by eIF2α phosphorylation (Fig. 11A). 
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Figure 11. DHT induces phosphorylation of eIF2α in an AR-dependent manner.  
A) Representative western blots indicating an increase in eIF2α-P in response to DHT addition in 
22Rv1 cells. This effect was abrogated in PC3 cells, which do not express AR (right). ATF4 
protein levels were measured as a positive control since it is induced by eIF2α-P. β-actin was 
used as a loading control. B) Addition of 20 µM bicalutamide to 22Rv1 cells prevented the 
increase in eIF2α-P observed after addition of DHT. β-tubulin or β-actin were used as loading 
controls. 
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eIF2α phosphorylation is essential for increased TMEFF2 translation in response to  
androgens 
To further investigate the role of eIF2α phosphorylation and androgens on the translation 
of TMEFF2, mouse embryonic fibroblasts (MEFs) expressing either wild-type eIF2α (wt/wt) or 
an eIF2α S51A (A/A) mutant form, carrying a Ser to Ala mutation that prevents eIF2α-P, were 
transfected with the pTM1234-Gluc reporter and expression of the reporter was analyzed in the 
presence and absence of different concentrations of thapsigargin. This experimental system was 
tested by treating the cells with clotrimazole or thapsigargin, two drugs known to promote eIF2α-
P. Both effectively promoted eIF2α-P in cells carrying the wild-type but not the S51A (A/A) 
mutant eIF2α (Fig. 12A). Cells were grown in phenol red-free media supplemented with CSS 
and treated with different concentrations of thapsigargin. When expression of the pTM1234-Gluc 
reporter was analyzed in conditioned media from the wt/wt and A/A MEFs lines, increased 
luciferase activity was detected in response to thapsigargin in cells carrying the wild-type eIF2α 
but not in the eIF2α S51A mutant cells (Fig. 12B).  Similarly, only the cells carrying the wild-
type eIF2α allele were able to induce translation of the ATF4 protein used as a positive control 
for eIF2α-P (Fig. 12B). Altogether these results confirm that eIF2a-P is required for the DHT-
induced translation of TMEFF2.  
 
 
64 
 
(eIF2 -wt) (eIF2 -S51A)
A MEF S/S MEF A/A
0
0.5
1
1.5
2
2.5
3
3.5
0 0.1 0.5
N
o
rm
a
li
z
e
d
 lu
c
if
e
ra
s
e
 a
c
ti
v
it
y
 
(f
o
ld
 o
f 
n
o
 t
h
a
p
s
ig
a
rg
in
)
Thapsigargin concentration ( M)
MEF eIF2 wt (S/S)
B
**
*
: eIF2
: eIF2 -P
0
0.5
1
1.5
0 0.1 0.5
N
o
rm
a
li
z
e
d
 lu
c
if
e
ra
s
e
 a
c
ti
v
it
y
 
(f
o
ld
 o
f 
n
o
 t
h
a
p
s
ig
a
rg
in
)
Thapsigargin concentration ( M)
MEF eIF2 mut (A/A)
C
(eIF2 -wt) (eIF2 -S51A)
MEF S/S MEF A/A
: ATF4
: tubulin
7
(eIF2 -wt)(eIF2 -S51A)
MEF S/SMEF A/A
 
Figure 12.  Increased TMEFF2 translation in response to androgens requires eIF2α-P.  A) 
Western blot showing total and phophorylated eIF2α in wild-type and A/A MEF cells treated 
with the indicated amounts of thapsigargin or clotrimazole.  B) Gaussia luciferase levels were 
measured in wt/wt and A/A MEF cells treated with the indicated amounts of thapsigargin for 3 
hrs and normalized to Seap expression.  Luciferase/Seap values for the vehicle-treated cells are 
set to 1.  C) As a positive control for eIF2α-P, western blot analysis demonstrates that ATF4 
protein expression is increased in wt/wt MEF cells treated with thapsigargin.  β-tubulin was used 
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as a loading control.  Data shown are mean ± S.D. of at least three independent experiments with 
multiple replicates. *, p < 0.05, and **, p < 0.01. 
 
 
 
Conditions that promote eIF2α-P result in increased TMEFF2 translation  
In order to determine whether eIF2α 
translation of TMEFF2, 22Rv1 cells were treated with clotrimazole, a drug that causes depletion 
of intracellular Ca
2+
 stores resulting in activation of the PKR kinase and subsequent eIF2α-P, and 
the effect on TMEFF2 translation was analyzed using polysome analysis. Western blot analyses 
indicated that the clotrimazole treatment resulted in increased phosphorylation of eIF2α in 
22Rv1 cells (Fig. 13A). As previously described (4), clotrimazole treatment resulted in reduced 
polysomes along with an increase in monosomes indicating inhibition of translation initiation 
(Fig. 13B). Under these conditions, we observed a shift of the TMEFF2 mRNA towards the 
heavier polysomal fractions when compared to the DMSO-treated controls (Fig. 13B and 13C), 
suggesting that clotrimazole treatment increased translation of the TMEFF2 mRNA. However, 
the shift was small, likely reflecting the presence of multiple uORFs and a complex translational 
regulatory mechanism.  Similar results were observed in other cell lines (data not shown). 
Confirming these results, clotrimazole treatment of cells containing the pTM1234-Gluc reporter 
resulted in a significant increase in luciferase activity (data not shown). In addition, a shift to the 
heavier polysomal fractions was also observed for the uORF-containing ATF4 mRNA, known to 
be preferentially translated upon eIF2α-P (Fig. 13B and 13C; (45)). Taken together, these results 
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demonstrate that eIF2α phosphorylation, independent of the causative stimulus, is sufficient to 
enhance translation of TMEFF2.  
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Figure 13.  TMEFF2 mRNA associates with heavier polysomes in response to ER stress.   
A) Western blot indicating phosphorylation of eIF2α in response to ER-stress inducing agents in 
22Rv1 cells. B) 22Rv1 cells were exposed to 15 µM clotrimazole or vehicle control for 1 hr and 
lysates subjected to polysome analysis. Total RNA was prepared from the fractions, and the 
percentage of  TMEFF2, ATF4, and ACTB mRNAs present in each fraction were determined by 
qRT-PCR. A representative example of one of the three independent experiments is shown. C) 
Quantitation of the qRT-PCR results presented in B). 
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Discussion 
 
 Changes in the expression of TMEFF2 protein have been documented in prostate cancer, 
and a potential role for TMEFF2 in this disease has been proposed (3, 35, 39, 71). However, the 
molecular mechanisms leading to the deregulation of TMEFF2 expression in prostate cancer are 
not known. The present study reveals a novel role for androgens in the regulation of TMEFF2 
translation that could account for the changes in TMEFF2 expression observed in prostate 
cancer. We demonstrate that androgen signaling promotes increased TMEFF2 translation 
through a mechanism that involves the phosphorylation of eIF2α and is dependent on the 
presence of uORFs in the 5’-UTR of the TMEFF2 mRNA. 
 The main androgen, testosterone, and its metabolite, DHT, largely mediate their effect 
through binding to the AR, a ligand-inducible transcription factor. The bound AR can recognize 
and bind specific androgen response elements in the promoter regions of target genes, causing 
activation or repression of transcription, leading to subsequent changes in protein synthesis (8). 
However, post-transcriptional regulation of gene expression by androgens has also been 
documented, affecting mRNA stability, protein localization, polyA-tail length, and translation 
efficiency (75, 80). The effect of androgens on translation is mediated through several 
mechanisms including changes in miRNA expression or processing (32), phosphorylation of 
translation factors like eEF2 (43), or mTOR activation-mediated phosphorylation of p70S6 and 
4E-BP1 (108). The results presented here indicate that physiological concentrations of DHT 
promote eIF2α phosphorylation in prostate cancer cell lines to influence translation.  
 Phosphorylation of eIF2α ultimately leads to the inhibition of global translation initiation 
along with stimulation of translation of specific mRNAs, i.e. uORF-containing mRNAs. These 
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changes facilitate cellular adaptation to the stress conditions promoting either survival or 
initiation of apoptosis (85). Using TMEFF2-Luciferase reporter constructs in which the 5’-UTR 
of TMEFF2 was fused to the Gaussia Luciferase gene, we demonstrated that, in addition to 
eIF2α-P, DHT also promotes translation of TMEFF2. Importantly, this effect requires the 
presence of uORFs in the 5’-UTR of the TMEFF2 mRNA, as DHT showed no effect on the 
translation of a TMEFF2-Luciferase reporter in which the AUGs for each of the uORFs were 
mutated. Supporting these results, translation of the TMEFF2 endogenous protein and the uORF 
containing ATF4 transcriptional regulator, (known to be regulated by eIF2α-P) were also 
increased in response to DHT stimulation. Moreover, as previously demonstrated for ATF4 (81), 
using polysome analysis we observed that translation of TMEFF2 increased in response to 
clotrimazole, a translation inhibitor that promotes ER stress and subsequent eIF2α-P. In addition, 
the DHT effect on TMEFF2 translation was not observed in cells carrying a non-
phosphorylatable form of eIF2α. These results suggest that the effect of DHT on TMEFF2 
expression was mediated by eIF2α-P. We also demonstrated that the DHT effect on TMEFF2 
expression required the presence of a functional AR, but was partially independent of 
transcriptional activity. To our knowledge, this is the first report demonstrating a transcription-
independent effect of DHT on translation of uORF-containing mRNAs through phosphorylation 
of eIF2α.  
 Phosphorylation of eIF2α in response to different forms of stress is mediated by one of 
the following four kinases (19): protein kinase R (PKR), heme-regulated eIF2α 
protein kinase R-like kinase (PERK), or GCN2 (general control nonderepressible-2. Several 
different kinases might be responsible for eIF2α phosphorylation in response to DHT. Androgens 
regulate the transcription of many genes, including some of those involved in amino acid 
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metabolism (46, 75), and it is therefore possible that DHT-induced eIF2α phosphorylation results 
from GCN2 activation driven by metabolic changes. However, under our experimental 
conditions, DHT stimulated the translation of TMEFF2 in the presence of actinomycin D (data 
not shown), suggesting that the DHT-induced phosphorylation of eIF2α is, at least partly non-
genomic. While this manuscript was in preparation, Dai and collaborators (22) reported 
increased apoptosis of human liver cells in response to DHT administration through a PKR-
eIF2α-P dependent mechanism. This effect was sensitive to the AR antagonist flutamide and it 
seemed to involve CHOP (GADD153) activation. These results suggest that DHT functions by 
activating PKR, however, the experiments were performed in the presence of 100 nM DHT, a 
concentration much higher than physiological levels (1-10 nM). In this regard, studies in mice 
indicate that excess androgens can promote oxidative stress (67), which can induce PKR activity 
and phosphorylation of eIF2α (33). In cell lines, addition of physiological levels of DHT can 
promote increased cytosolic calcium (Ca
2+
), which can promote PRK activation either directly or 
indirectly by increasing oxidative stress (33). Therefore, DHT could indirectly promote PKR 
activation through its ability to promote accumulation of intracellular calcium, a well-known 
transcription independent, non-genomic effect of androgen.  
 What is the role of AR-mediated phosphorylation of eIF2α in prostate cancer? A 
correlation between translation initiation and prostate cancer can be postulated from the 
observation that several translation initiation factors are overexpressed or activated in this 
disease (21). For example, eIF3h and eIF4E are frequently overexpressed in advanced prostate 
cancers, together with increased phosphorylation of eIF4E and eIF4E-BP1, which support 
increased translation (91). However, the role of eIF2α-P in prostate or other cancers is not clear.  
While expression of a nonphosphorylatable form of eIF2α or overexpression of a dominant-
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negative form of PKR have been shown to inhibit apoptosis and cause malignant transformation, 
other reports indicated that reduced PKR levels correlated with less aggressive tumors (91). In 
general, it has been suggested that the role of eIF2α-P is dependent on the stage and grade of the 
disease, occurring at the earliest stages as a response to stress, while downregulation of eIF2α-P 
will occur later on as a result of the selective pressure imposed by the tumor cell’s need to 
proliferate (21). Androgen signaling is critical for the progression of prostate cancer, and 
changes in the sensitivity to androgen signaling after prostate cancer regression drives the cancer 
to the advanced stages. It is possible that early in prostate cancer, or after regression, androgen 
signaling triggers PKR activation and subsequent eIF2α-P, leading to anti-proliferative effects, 
apoptosis, and the activation of tumor suppressor mechanisms. In this respect, it has been 
reported that the anti-proliferative and pro-apoptotic effects of PTEN, a tumor suppressor protein 
frequently mutated in prostate cancer, require activation of the PKR-eIF2α-P pathway (74). 
Persistent AR signaling along with downregulation of eIF2α-P may lead to AR-mediated 
transcriptional events and tumor progression.   
 In summary, our findings reveal a novel role for AR signaling as a translational regulator 
of TMEFF2 through the phosphorylation of eIF2α. We have previously demonstrated that the 
tumor suppressor ability of TMEFF2 partly correlates with its ability to interact with SARDH 
and modulate the levels of sarcosine (17). SARDH and GNMT, the enzymes that catalyze the 
forward and reverse conversion of sarcosine into glycine, are under transcriptional control 
mediated by the androgen receptor. Treatment of prostate cancer cell lines with androgens 
resulted in an increase in GNMT expression and a simultaneous decrease in SARDH levels (93). 
Since TMEFF2 is both transcriptionally (35) and translationally regulated by androgens, these 
observations potentially link androgens with the regulation of sarcosine metabolism and changes 
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in TMEFF2 expression, and may suggest a model by which in the early stages of tumorigenesis 
the increased expression of TMEFF2 in response to androgens is a cellular response to overcome 
tumorigenesis. Persistent AR signaling leads to an increase in GNMT and a simultaneous 
decrease in SARDH expression that outweigh the effect of increased TMEFF2 levels. Therefore, 
TMEFF2 upregulation in response to AR signaling may initially serve as a barrier for malignant 
progression of prostate cancer.  
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CHAPTER 5 
 
GENERATION AND CHARACTERIZATION OF A TRANSGENIC MOUSE MODEL 
OVEREXPRESSING TMEFF2 IN THE PROSTATE 
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Introduction 
 
 The complex biology of the TMEFF2 protein has made it difficult to fully understand the 
biological function of TMEFF2 in the prostate and in prostate tumorigenesis.  Although previous 
reports using cell lines and primary cells have provided important clues into its function and 
mechanism of action as a tumor suppressor, it is critical to evaluate the function of TMEFF2 in a 
mammalian model and an environment that is biologically similar to that of the human prostate.  
The mouse prostate divided into four lobes, the anterior, ventral, dorsal, and lateral lobes.  The 
dorsal and lateral lobes are usually grouped together as the dorsolateral lobe.  The dorsolateral 
lobe is believed to be most similar to the human peripheral zone where the majority of prostate 
tumors originate.   Although mice do not spontaneously develop prostate tumors naturally, most 
genetic mouse models of prostate cancer develop PIN and prostate cancer in the dorsolateral lobe 
that shares many of the histological features and often similar genetic signatures as human 
prostate cancer (59, 105). 
TMEFF2 expression in the adult mouse is restricted to the brain (39), however it is also 
expressed in the mid to late stages of embryogenesis, suggesting it may play a role in 
development (99).  A potential role for TMEFF2 in embryonic development is intriguing as 
developmental pathways are often reactivated in several types of cancer including prostate 
cancer (7), and may provide insight into the mechanism(s) of TMEFF2 action in tumorigenesis.  
As mentioned, the other TMEFF family member, TMEFF1, can modulate Nodal signaling, an 
embryonic developmental pathway that is re-activated in human cancers and promotes 
tumorigenicity (13, 36).  An evaluation of TMEFF2 function in a transgenic mouse model may 
provide important information into its role in development/tumorigenesis. 
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TMEFF2 knockout mice have been developed by two separate groups and in both cases 
resulted in pups that died at weaning (16, 52).  The mice survived to birth, but the phenotypic 
analysis of the TMEFF2 knockout was limited due to the very short lifespan of the pups.  
However, it was observed that the mice had empty stomachs at the time of death and it was 
suggested that this may have been due to a neuronal defect affecting the ability to masticate the 
mouse diet (52).  Chen et al. showed that the TMEFF2 knockout mice were of a significantly 
smaller size than wild-type mice, but otherwise found no structural or molecular defects in the 
brains of these mice or changes in prostate morphology (16).  Although the results of this model 
are intriguing with respect to its role in brain development, it offered little insight into its role in 
prostate tissue or in tumorigenesis.   In order to study the role of TMEFF2 in the 
development/homeostasis of the mouse prostate and its role in prostate cancer, we constructed a 
novel mouse model with prostate-specific TMEFF2 overexpression driven by the androgen-
regulated probasin promoter (PB-TMEFF2). 
Here we describe the generation of the PB-TMEFF2 transgenic mouse model and its 
initial characterization.  Two PB-TMEFF2 mouse lines were established that express high levels 
of TMEFF2 in the prostates of transgenic mice. These mice display a normal development and 
no gross phenotypic effects as a result of TMEFF2 overexpression, and an examination of 
prostate tissue sections from control and transgenic mice revealed no abnormalities in the 
architecture of the glands.  These sections were also examined for evidence of hyperplasia, PIN, 
or prostate carcinoma to rule out the possibility that TMEFF2 alone can promote prostate tumor 
initiation.  Transgenic prostates did not show evidence of tumorigenesis being initiated as a 
result of TMEFF2 expression. 
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Results 
 
Construction of the PB-TMEFF2 Transgenic Expression Construct 
To evaluate the functional role of TMEFF2 in prostate development and in prostate 
tumorigenesis, we developed a novel transgenic mouse model which overexpressess TMEFF2 
specifically in prostate tissue. The objective in designing the transgene expression vector was to 
achieve high levels of TMEFF2 expression exclusively in the prostate and to ensure the highest 
chance of success for transgene integration into the genome.  The pTg1 expression vector 
(provided by Dr. R. Thresher, UNC-Chapel Hill) contains two multiple cloning sites separated 
by an intronic sequence of the mouse transthyretin gene. To achieve high levels of prostate-
specific TMEFF2 expression we utilized a modified version of the rat probasin (PB) gene 
promoter, the ARR2PB composite probasin promoter (from Dr. R. Matusik, Vanderbilt 
University), that has been extensively characterized in the production of transgenic animals 
(109). The ARR2PB promoter was inserted into Exon 1 position, which is followed by the 
transcription start site, and human full-length TMEFF2 cDNA was inserted into Exon 2 position.  
Immediately downstream from Exon 2 is an SV40 early-region polyadenylation signal sequence 
(Fig. 14A).   
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Figure 14 . Generation and characterization of PB-TMEFF2 transgenic mice.  A) Linear 
transgene expression vector used to inject into mouse embryos.  Arrows indicate the positions of 
primer binding for genotyping by PCR.  B) Illustration depicting the lobes of the mouse prostate 
and other parts of the urogenital system.  Prostatic lobes are highlighted in yellow.  The dorsal 
and lateral prostatic lobes are often grouped together as the dorsolateral prostate.  C)  Western 
blot showing TMEFF2 expression in the anterior, ventral, and dorsolateral prostatic lobes of a 
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heterozygous (PB-TMEFF2 +/-) and wild-type (WT) littermate from line 478. D) 
Immunohistochemistry staining for TMEFF2 protein in a heterozygous PB-TMEFF2 ventral 
prostate (left) and a wild-type littermate (right). 
 
Generation and Identification of PB-TMEFF2 Transgenic Mice 
The transgenic expression vector was injected into C57BL/6 X DBA2 hybrid embryos to 
produce transgenic founder mice by the UNC-Chapel Hill animal models core facility according 
to established methods (49).  Transgenic F0 mice (first generation following pronuclear 
injections) were identified by DNA extraction from tail snips followed by PCR with primers 
specific for the PB-TMEFF2 transgene (Fig. 14A), and 8 mice were initially identified that 
carried the transgene out of a total of 31 FO mice (resulting from 2 pronuclear injections and 
subsequent implantations).  All 8 transgene-positive F0 mice were male, and each was crossed 
with a wild-type C57BL/6 female to produce F1 offspring that are heterozygous for the transgene 
if it is transmitted.  Transgenic DNA must be incorporated into the germ cells of the F0 mice in 
order for the foreign DNA to be transmitted to offspring of the F1 generation.  We therefore used 
PCR genotyping to identify the F1 pups that inherited the transgenic DNA.  Two of the founder 
mice (#478 and #485) transmitted the transgenic DNA and resulted in the generation of two 
independent mouse lines to study TMEFF2 function. 
 
Necropsy and Preliminary Evaluation of TMEFF2 Effects on Prostate Tissue 
 Post-pubescent mice from lines 485 and 478 were sacrificed and the prostates removed 
and separated into individual lobes.  To assess levels of TMEFF2 protein expression in the 
individual lobes of the mouse prostates, protein was prepared from each prostatic lobe for 
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western blotting, consisting of the anterior, ventral, and dorsolateral lobes (Figure 14B).  We 
observed TMEFF2 protein expression in each lobe of prostates from transgenic mice and no 
TMEFF2 expression in prostatic lobes from wild-type control mice (Fig. 14C).  A greater 
amount of TMEFF2 expression was observed in the prostates of transgenic mice of line 478 than 
in line 485.  The pattern of expression in the different lobes, however, was the same in both 
transgenic lines.  The highest levels of TMEFF2 protein expression were detected in the ventral 
lobe, followed by the dorsolateral lobe, and minimal expression was detected in the anterior 
prostatic lobe.  This pattern of expression in the prostatic lobes is consistent with previously 
reported transgenic mouse lines with probasin promoter-driven gene expression (109).  TMEFF2 
overexpression was also demonstrated by immunohistochemistry in the ventral lobe of a 
heterozygous PB-TMEFF2 mouse and no TMEFF2 was detected in a wild-type littermate (Fig. 
14D). 
To examine the effect of TMEFF2 overexpression on the prostate development, 
heterozygous male transgenic mice were sacrificed at various ages ranging from 6 to 70 wks 
along with male age-matched, wild-type littermates as controls.   Transgenic mice from each 
litter were identified by PCR with transgene-specific primers (Table 1).  There were no apparent 
developmental/behavioral abnormalities in the transgenic mice, and the litter sizes produced by 
transgenic males were normal relative to wild-type males.  Additionally, a gross examination of 
transgenic urogenital organs likewise reveals no differences with the control groups.  A 
pathological examination of prostate tissue sections did not reveal an effect of TMEFF2 
overexpression on the development of the prostate, and the glandular architecture in each lobe 
was normal relative to those of wild-type littermates.   Furthermore, there was no induction of 
PIN or cancer in the transgenic mice, suggesting that TMEFF2 alone does not promote cancer 
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initiation.  The lack of tumor initiation is consistent with a role for TMEFF2 as a tumor 
suppressor; however, its function in later stages of prostate cancer remains to be evaluated. 
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Discussion 
 
Here we show the generation of a novel transgenic mouse model overexpressing 
TMEFF2 in the prostate and initiate its characterization.  This model was constructed with the 
hopes of enhancing our understanding of the functional role of TMEFF2 in the prostate and in 
prostate tumorigenesis.  The results presented here represent a preliminary evaluation of the 
functional role of TMEFF2 in the development of the mouse prostate, and an initial step in an 
examination of the role of TMEFF2 in prostate cancer.  A role for TMEFF2 in the development 
or function of the prostate was not identified in this study as no abnormalities were found in 
either gross or microscopic examinations of transgenic prostate tissue. It is important to note, 
however, that the induction of transgene expression using the ARR2PB promoter remains at very 
low levels until about 5 wks of age in mice (109), and therefore an influence of TMEFF2 on the 
early stages of prostate development may not be detected using this model.  No induction of PIN 
or any evidence of prostate cancer suggests that TMEFF2 on its own does not have a role in the 
initiation of prostate cancer, consistent with our proposed role for TMEFF2 as a tumor 
suppressor.  However, the effects of TMEFF2 overexpression on the entire course of prostate 
tumorigenesis were not addressed in these studies.   
The PB-TMEFF2 mouse model will be a valuable tool to study the role of TMEFF2 in 
prostate tumorigenesis by crossing it with genetically engineered mouse models of prostate 
cancer that progress through all stages of prostate tumorigenesis.  For instance, the transgenic 
TRAMP mouse model develops prostate cancer foci as a result of the prostate-specific 
expression of the SV40 T antigen.  Pathologically the tumors that develop in this model closely 
mimic the human disease state and rapidly progress to invasive carcinoma and metastasis (38).  
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The PB-TMEFF2 transgenic model presented here will be crossed with the TRAMP model in 
future studies in order to evaluate its role in the development and progression of prostate cancer 
in a mammalian model.  Based on our results that TMEFF2 overexpression does not lead to 
tumor development in the mouse prostate, coupled with the tumor suppressor effects observed 
for full-length TMEFF2 in cell culture (see chapter 3), we propose that in normal tissue and early 
stages of cancer development TMEFF2 may function as a tumor suppressor.  We therefore 
expect that TMEFF2 will initially suppress tumor growth and delay the progression of the 
cancer.  However, excess levels of inflammatory cytokines in the growing tumor would likely 
induce the cleavage of TMEFF2. If this is the case, the upregulation of TMEFF2 would have the 
opposite effect as the full-length TMEFF2 and instigate tumor progression in the later stages.  
This theory is in line with the evidence that TMEFF2 is overexpressed in prostate cancer tissue 
relative to benign tissue (39, 71), which is generally an occurrence that is associated with 
oncogenes.  The PB-TMEFF2 model can also be utilized to study the influence of TMEFF2 
overexpression on prostate tissue regeneration following castration.  As mentioned, castration 
leads to massive apoptosis in the prostate which will re-form upon the return of androgen 
signaling. The delayed expression of TMEFF2 (until ~ 5 wks) in the PB-TMEFF2 model limits 
our ability to assess the effects of TMEFF2 overexpression on prostate development, much of 
which occurs during the 1-5 wk period after birth (14). An examination of the effects of 
TMEFF2 overexpression on prostate tissue regeneration can be performed in post-pubescent 
(TMEFF2 expressing) mice and may reveal a role for TMEFF2 in prostate development. 
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CHAPTER 6 
 
DISCUSSION 
An influential role for TMEFF2 in the establishment and/or progression of prostate 
cancer is suggested by its upregulation in a significant fraction of prostate cancers and its limited 
expression in other tissues (39, 71, 99).  The potential for TMEFF2 to influence signaling 
pathways in prostate cancer cells is highlighted by its EGF-like and follistatin domains, capable 
of modulating growth factor pathways with well established roles in tumorigenesis (5, 99), as 
well as a putative G-protein-activating motif at its C-terminus. Although some significant 
insights into its function have been revealed since it was originally cloned, its role in prostate 
cancer has remained poorly understood.  In order for the treatment of prostate cancer to move 
towards novel therapies, substantial improvements in understanding the molecular basis of 
disease progression are needed, particularly of the factors that drive its progression and the 
pathways that lead to their deregulation. 
In the studies presented here, an evaluation of the phenotypic effects of TMEFF2 
overexpression in vitro and in vivo demonstrates its tumor suppressor function.  Results from 
phenotypic assays show that its tumor suppressive activity is pleiotropic, capable of blocking cell 
invasion, reducing proliferation rates, antagonizing cell survival, and inhibiting anchorage-
independent growth.  The potential for TMEFF2 to suppress several tumorigenic hallmark traits 
makes it difficult to point to a certain stage/phase of disease progression in which the tumor 
suppressor primarily functions. With the described functional effects, TMEFF2 could 
presumably influence multiple disease stages and suppress tumor progression, from the earliest 
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tumor stages to metastasis.  These in vitro results are supported by the inhibition of subcutaneous 
TRAMP-C2 tumor development in an allograft model when TMEFF2 is expressed.    
Although our results demonstrate a role for the full-length TMEFF2 as a tumor 
suppressor, it is reasonable to suspect that the function of TMEFF2 may change throughout the 
progression of prostate cancer.  This possibility is based on previous results that have 
demonstrated opposing influences of the full-length and ectodomain forms of TMEFF2 on 
cancer cells, suggesting a potential dual function in prostate cancer (5, 17).    An abundance of 
genetic and environmental changes that occur during the course of tumorigenesis can modulate 
the function of some genes, and several genes have been demonstrated to have dual roles in 
tumorigenesis with functions that can be dependent on the cancer stage, activated oncogenic 
pathways, or other environmental factors (2, 20).  Ultimately, we believe that the effects of 
TMEFF2 overexpression on prostate tumorigenesis are dependent on whether the full-length 
(membrane-bound) form predominates or if it exists mostly as a cleaved ectodomain in the tumor 
environment.  A potential pro-tumorigenic role at later stages of disease progression would be 
consistent with the observation that TMEFF2 is upregulated in advanced prostate cancer, 
generally a characteristic of an oncogene. 
The observation that androgens can stimulate a post-transcriptional increase in TMEFF2 
expression suggests a possible mechanism by which TMEFF2 is overexpressed in prostate 
cancer.  Both the normal prostate and prostate cancer are critically reliant on androgen signaling 
pathways, and evidence has surfaced in recent years that the post-transcriptonal regulation of 
gene expression by androgens may have a central role in prostate carcinogenesis (48, 108). We 
therefore investigated the post-transcriptional mechanisms controlling TMEFF2 expression and 
the regulatory connection to androgen signaling.  Our results demonstrate that TMEFF2 is 
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translationally regulated by androgen signaling through several uORFs in its 5’ UTR.  Upon 
androgen stimulation, its translation is selectively increased through the AR-dependent induction 
of eIF2α-P in prostate cancer cells.  Although the functional effects of eIF2α-P in tumorigenesis 
are not well understood, modulating its activity could have a profound impact on cell behavior 
through the selective regulation of uORF-containing transcripts. A regulatory connection 
between AR signaling and the major translational regulators may represent a novel means to 
block the tumorigenic effects of androgens and the AR in prostate cancer.  This is exemplified by 
the recent development of a novel mTOR inhibitor, INK128, that demonstrated a strong 
inhibition of prostate cancer invasion and metastasis in vivo by blocking 4EBP1 phosphorylation 
and is currently in clinical trials (48).  As previously mentioned, mTOR is activated by androgen 
signaling (108) and drives prostate cancer cell invasion through the modulation of eIF4E 
availability (48).  These results highlight the promise of identifying and therapeutically targeting 
specific translational components, particularly the major regulators, that are influenced by 
androgen signaling.   
We propose a model in which TMEFF2 is expressed in normal prostate tissue and exists 
primarily in a membrane-bound form that functions as a tumor suppressor (Fig. 15). Based on 
previous data, its role as a tumor suppressor may be mediated in part by modulating intracellular 
sarcosine levels and/or modulating PDGF signaling.  Upon tumor initiation/progression 
TMEFF2 expression is increased, potentially as a means to suppress tumor growth or 
progression.  This effect is mediated by AR transcriptional and/or translational stimulation.  
However, the inflammatory conditions in the tumor microenvironment would presumably 
stimulate TMEFF2 cleavage by ADAM proteinases and lead to increased ectodomain levels.  
The cleavage of TMEFF2 causes a switch in TMEFF2 function from a tumor suppressor to an 
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oncogene, promoting the advance to late stages of prostate cancer by increasing proliferation 
rates/survival of the cancer cells.  Based on the model presented here, it is critically important to 
better understand the mechanism of TMEFF2 shedding from the membrane and at what stage in 
prostate tumor progression this occurs.  Since the full-length TMEFF2 suppresses tumorigenicity 
while the ectodomain may drive it, the inhibition of its cleavage may represent a promising 
therapeutic strategy. 
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Figure 15.  Model of TMEFF2 action in the course of prostate tumorigenesis.  TMEFF2 is 
primarily membrane-bound and signals as a tumor suppressor in normal prostate epithelium and 
early stages of tumorigenesis.  Upon the growth and progression of prostate tumor foci, AR 
activity leads to increased TMEFF2 expression either transcriptionally or at the level of 
translation through increased eIF2α-P.  TMEFF2 likely functions as a tumor suppressor until 
pro-inflammatory cytokines build up in the tumor environment, stimulating TMEFF2 cleavage 
from the membrane by ADAM proteinases.  Its cleavage from the membrane may represent a 
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change in TMEFF2 function from a tumor suppressor to an oncogenic role.  Advanced, 
castration-resistant prostate cancers are characterized by deregulated androgen signaling, which 
would lead to elevated TMEFF2 expression and potentially promote its progression to terminal 
stages. 
 
 
Finally, we have presented the generation and initial characterization of the PB-TMEFF2 
transgenic mouse model overexpressing TMEFF2 specifically in prostate tissue.  The PB-
TMEFF2 model will be a crucial tool in the examination of TMEFF2 function in prostate cancer.  
Crossing the PB-TMEFF2 model with the TRAMP prostate cancer model will allow for the 
evaluation of TMEFF2 function in the entire course of prostate cancer progression, from disease 
initiation to metastasis.    We expect that the TRAMP mice that overexpress TMEFF2 will have a 
delayed onset of tumor progression as a result of its tumor suppressor activity; however, upon 
tumor development we believe that TMEFF2 will accelerate tumor progression and metastasis as 
a result of increased levels of TMEFF2 ectodomain signaling.  The PB-TMEFF2 x TRAMP 
model will provide valuable information on the levels of TMEFF2 ectodomain that are shed from 
the membrane throughout tumor progression by its detection in plasma and/or urine, and 
increases in ectodomain levels in these fluids should coincide with the onset of disease 
progression.  Additionally, its restricted tissue distribution and cleavage from the membrane also 
make TMEFF2 a promising diagnostic or prognostic biomarker, and this possibility will be 
evaluated using the PB-TMEFF2 mouse model. 
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